FGFR2 (Fibroblast Growth Factor Receptor 2) encodes a receptor tyrosine kinase that mediates FGF signaling in development, tissue repair, and homeostasis. CRITICAL ISOFORM BIOLOGY: Alternative splicing of exon IIIb vs IIIc in the third Ig-like domain creates isoforms with MUTUALLY EXCLUSIVE ligand specificities: (1) FGFR2IIIb (P21802-3, KGFR) is expressed in EPITHELIAL cells and binds FGF1, FGF3, FGF7 (KGF), and FGF10. FGF7 and FGF10 bind ONLY to IIIb. (2) FGFR2IIIc (P21802-1, BEK) is expressed in MESENCHYMAL cells and binds FGF1, FGF2, FGF4, FGF6, and FGF9. FGF2 binds preferentially to IIIc. This isoform switching enables PARACRINE signaling between epithelium and mesenchyme: mesenchyme produces FGF7/10 to signal to epithelial IIIb, while epithelium produces FGF2/4 to signal to mesenchymal IIIc. Critical for limb development, lung branching morphogenesis, and wound healing. Additional isoforms: Secreted/soluble forms (P21802-14, P21802-19) may act as decoy receptors. Numerous other splice variants exist with various domain combinations. Cancer relevance: IIIb-to-IIIc isoform switching accompanies epithelial-mesenchymal transition (EMT) and correlates with metastatic potential in some cancers.
| GO Term | Evidence | Action | Reason |
|---|---|---|---|
|
GO:0005007
fibroblast growth factor receptor activity
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: FGFR2 is unambiguously a fibroblast growth factor receptor. UniProt confirms it is a "Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors." This applies to all transmembrane isoforms (both IIIb/KGFR and IIIc/BEK), though with different ligand specificities. Deep research confirms FGFR2 as a receptor tyrosine kinase whose primary function is transducing FGF signals via autophosphorylation and downstream pathway activation.
Reason: Core molecular function of FGFR2. Extensive experimental evidence from multiple studies (PMID:8663044, PMID:16597617, PMID:15629145) demonstrates FGF receptor activity. The IBA annotation appropriately captures the conserved function.
Supporting Evidence:
UniProtKB:P21802
Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors
file:human/FGFR2/FGFR2-deep-research-falcon.md
FGFR2 is a member of the FGFR receptor tyrosine kinase family that transduces extracellular fibroblast growth factor (FGF) signals into intracellular phosphorylation-dependent signaling programs that control proliferation, survival, differentiation, and migration.
|
|
GO:0005886
plasma membrane
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: Plasma membrane localization is confirmed for all transmembrane FGFR2 isoforms (IIIb and IIIc). However, secreted isoforms (P21802-14, P21802-19) are not plasma membrane-localized. The annotation is appropriate at the gene level since most functional isoforms are transmembrane.
Reason: UniProt confirms "Cell membrane; Single-pass type I membrane protein" for main isoforms. Extensive localization data supports plasma membrane localization for functional receptor isoforms.
Supporting Evidence:
UniProtKB:P21802
SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane protein
|
|
GO:0008284
positive regulation of cell population proliferation
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: FGFR2 signaling promotes cell proliferation in keratinocytes and immature osteoblasts. UniProt notes it "Promotes cell proliferation in keratinocytes and immature osteoblasts." This is a well-established downstream effect of FGF signaling through both IIIb and IIIc isoforms.
Reason: Core biological process for FGFR2. Multiple studies demonstrate proliferative effects (PMID:8663044, PMID:15629145, PMID:16597617). This applies to both major splice variants with different ligands driving the same outcome.
Supporting Evidence:
UniProtKB:P21802
Promotes cell proliferation in keratinocytes and immature osteoblasts
|
|
GO:0008543
fibroblast growth factor receptor signaling pathway
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: FGFR2 is a core component of FGF receptor signaling. Ligand binding leads to receptor dimerization, autophosphorylation, and activation of downstream cascades including PLCG1, MAPK, and PI3K/AKT pathways.
Reason: Fundamental role of FGFR2. UniProt extensively documents signaling mechanism including phosphorylation of PLCG1, FRS2, and activation of RAS-MAPK and AKT pathways. Both IIIb and IIIc isoforms signal through these pathways.
Supporting Evidence:
UniProtKB:P21802
Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway
|
|
GO:0001525
angiogenesis
|
IBA
GO_REF:0000033 |
KEEP AS NON CORE |
Summary: FGF signaling through FGFRs is known to promote angiogenesis, particularly FGF2 signaling through FGFR2IIIc (mesenchymal isoform). However, this may be more prominent for FGFR1 in endothelial cells. The annotation is reasonable but likely represents a non-core function.
Reason: Angiogenesis is documented for FGF/FGFR signaling generally, but FGFR2's primary roles are in epithelial-mesenchymal signaling for organ development rather than vascular biology. This is a secondary rather than core function.
|
|
GO:0043410
positive regulation of MAPK cascade
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: MAPK cascade activation is a core downstream signaling event for FGFR2. UniProt confirms that FRS2 phosphorylation leads to recruitment of GRB2/SOS1 and activation of RAS-MAPK signaling.
Reason: Core signaling output of FGFR2. Well-documented in UniProt and multiple publications (PMID:15629145, PMID:17623664). Both IIIb and IIIc isoforms activate MAPK upon ligand binding.
Supporting Evidence:
UniProtKB:P21802
mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway
|
|
GO:0043235
receptor complex
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: FGFR2 forms homodimers upon ligand binding and also forms complexes with heparan sulfate proteoglycan co-receptors. UniProt confirms "Homodimer after ligand binding."
Reason: FGFR2 functions as part of a receptor complex including FGF ligands, heparan sulfate, and in some cases KLB (for FGF19/21). Dimerization is required for receptor activation.
Supporting Evidence:
UniProtKB:P21802
Monomer. Homodimer after ligand binding.
|
|
GO:0017134
fibroblast growth factor binding
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: FGFR2 binds multiple FGFs with isoform-specific preferences. IIIc (P21802-1) has high affinity for FGF1, FGF2; IIIb (P21802-3) has high affinity for FGF1, FGF7. CRITICAL ISOFORM NOTE - FGF7 binds ONLY to IIIb (epithelial); FGF2 binds preferentially to IIIc (mesenchymal).
Reason: Core molecular function. Extensive structural and biochemical data (PMID:8663044, PMID:10830168, PMID:12591959) document FGF binding. The annotation at gene level is appropriate though ligand specificity differs by isoform.
Supporting Evidence:
UniProtKB:P21802
Isoform 1 has high affinity for FGF1 and FGF2, but low affinity for FGF7. Isoform 3 has high affinity for FGF1 and FGF7
|
|
GO:0000166
nucleotide binding
|
IEA
GO_REF:0000043 |
ACCEPT |
Summary: FGFR2 is a tyrosine kinase that binds ATP for its catalytic activity. Nucleotide binding is accurate but overly general - ATP binding is more specific.
Reason: True but general. FGFR2 has a kinase domain that binds ATP. The more specific term "ATP binding" is also annotated and preferred.
|
|
GO:0004672
protein kinase activity
|
IEA
GO_REF:0000002 |
ACCEPT |
Summary: FGFR2 is a protein kinase. The annotation is correct but "protein tyrosine kinase activity" is more specific and preferred.
Reason: Correct parent term. FGFR2 has documented kinase activity (EC 2.7.10.1). More specific child term annotations also exist.
|
|
GO:0004713
protein tyrosine kinase activity
|
IEA
GO_REF:0000120 |
ACCEPT |
Summary: FGFR2 is a receptor tyrosine kinase that autophosphorylates and phosphorylates substrates including PLCG1, FRS2, and PAK4 on tyrosine residues.
Reason: Core molecular function. UniProt confirms EC 2.7.10.1 classification and documents phosphorylation of multiple substrates. Applies to all kinase- containing isoforms.
Supporting Evidence:
UniProtKB:P21802
Phosphorylates PLCG1, FRS2 and PAK4
|
|
GO:0004714
transmembrane receptor protein tyrosine kinase activity
|
IEA
GO_REF:0000003 |
ACCEPT |
Summary: FGFR2 is a single-pass type I transmembrane receptor tyrosine kinase. This is the most specific and appropriate molecular function term for membrane- bound isoforms.
Reason: Most specific appropriate MF term for transmembrane FGFR2 isoforms. Note that secreted isoforms (P21802-14, P21802-19) lack transmembrane domain and kinase activity.
|
|
GO:0005007
fibroblast growth factor receptor activity
|
IEA
GO_REF:0000120 |
ACCEPT |
Summary: Duplicate of IBA annotation. FGFR2 is unambiguously an FGF receptor.
Reason: Core function - duplicates IBA annotation with different evidence. Correct.
|
|
GO:0005524
ATP binding
|
IEA
GO_REF:0000120 |
ACCEPT |
Summary: FGFR2 kinase domain binds ATP. Crystal structures confirm ATP binding (PDB entries with ATP analogs).
Reason: Core function for kinase activity. Structural data confirms ATP binding site.
|
|
GO:0005576
extracellular region
|
IEA
GO_REF:0000044 |
ACCEPT |
Summary: The secreted/soluble isoforms (P21802-14 soluble KGFR, P21802-19 soluble KGFR) are found in the extracellular region. For transmembrane isoforms, the N-terminal region including Ig-like domains is extracellular.
Reason: Appropriate for secreted isoforms. UniProt confirms isoforms 8 (K-sam-IV, Soluble KGFR) and 13 (Soluble KGFR) are secreted forms that would localize to the extracellular region.
|
|
GO:0005794
Golgi apparatus
|
IEA
GO_REF:0000044 |
ACCEPT |
Summary: FGFR2 is N-glycosylated and transits through the Golgi. UniProt notes "N-glycan chains undergo further maturation to an Endo H-resistant form in the Golgi apparatus."
Reason: FGFR2 passes through Golgi during maturation. Also documented as "Golgi apparatus" in subcellular location. Represents trafficking intermediate.
Supporting Evidence:
UniProtKB:P21802
SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane protein. Golgi apparatus.
|
|
GO:0005886
plasma membrane
|
IEA
GO_REF:0000044 |
ACCEPT |
Summary: Duplicate of IBA annotation. Plasma membrane localization for transmembrane isoforms is well established.
Reason: Correct - duplicates IBA with different evidence.
|
|
GO:0006915
apoptotic process
|
IEA
GO_REF:0000043 |
KEEP AS NON CORE |
Summary: FGFR2 has complex effects on apoptosis - it can promote apoptosis in differentiated osteoblasts but inhibit it in keratinocytes and immature osteoblasts. The UniProt keyword may be too general.
Reason: UniProt notes FGFR2 "promotes apoptosis in differentiated osteoblasts" but this is context-dependent and not a primary function. The annotation is valid but represents a secondary/context-specific role.
Supporting Evidence:
UniProtKB:P21802
Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts
|
|
GO:0008201
heparin binding
|
IEA
GO_REF:0000043 |
ACCEPT |
Summary: FGFR2 binds heparan sulfate glycosaminoglycans which serve as coreceptors. Heparin (a highly sulfated heparan sulfate) is used experimentally.
Reason: Documented function. UniProt confirms "Affinity for fibroblast growth factors (FGFs) is increased by heparan sulfate glycosaminoglycans that function as coreceptors." Crystal structures show heparin binding (PMID:11069186).
Supporting Evidence:
UniProtKB:P21802
Affinity for fibroblast growth factors (FGFs) is increased by heparan sulfate glycosaminoglycans that function as coreceptors
|
|
GO:0008284
positive regulation of cell population proliferation
|
IEA
GO_REF:0000120 |
ACCEPT |
Summary: Duplicate of IBA annotation. FGFR2 promotes cell proliferation.
Reason: Correct - duplicates IBA with different evidence.
|
|
GO:0008543
fibroblast growth factor receptor signaling pathway
|
IEA
GO_REF:0000120 |
ACCEPT |
Summary: Duplicate of IBA annotation. FGFR2 is a core component of FGF signaling.
Reason: Correct - duplicates IBA with different evidence.
|
|
GO:0016020
membrane
|
IEA
GO_REF:0000002 |
ACCEPT |
Summary: Transmembrane FGFR2 isoforms are integral membrane proteins. This is a parent term of plasma membrane - overly general but not wrong.
Reason: Correct but general. More specific annotations (plasma membrane) exist.
|
|
GO:0016301
kinase activity
|
IEA
GO_REF:0000043 |
ACCEPT |
Summary: FGFR2 has kinase activity. This is a parent of the more specific protein tyrosine kinase activity annotations.
Reason: Correct but overly general. More specific annotations exist.
|
|
GO:0016740
transferase activity
|
IEA
GO_REF:0000043 |
ACCEPT |
Summary: Kinases are transferases (transfer phosphate groups). This is very general but technically correct.
Reason: Correct parent term. Very general but valid.
|
|
GO:0031410
cytoplasmic vesicle
|
IEA
GO_REF:0000120 |
ACCEPT |
Summary: FGFR2 is found in cytoplasmic vesicles during internalization after ligand binding. UniProt notes "After ligand binding, the activated receptor is rapidly internalized and degraded."
Reason: Valid location during receptor trafficking/internalization.
Supporting Evidence:
UniProtKB:P21802
After ligand binding, the activated receptor is rapidly internalized and degraded
|
|
GO:0033688
regulation of osteoblast proliferation
|
IEA
GO_REF:0000117 |
ACCEPT |
Summary: FGFR2 regulates osteoblast proliferation - it promotes proliferation in immature osteoblasts. This is relevant to craniosynostosis syndromes caused by FGFR2 mutations.
Reason: UniProt confirms FGFR2 "Promotes cell proliferation in keratinocytes and immature osteoblasts" and "Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis."
|
|
GO:0043009
chordate embryonic development
|
IEA
GO_REF:0000117 |
KEEP AS NON CORE |
Summary: FGFR2 is required for normal embryonic development. UniProt confirms it is "Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development."
Reason: Valid but very general developmental term. More specific developmental processes (limb, lung, skeleton) are better descriptors of FGFR2 function.
|
|
GO:0043410
positive regulation of MAPK cascade
|
IEA
GO_REF:0000117 |
ACCEPT |
Summary: Duplicate annotation (IBA already reviewed). MAPK cascade activation is a core downstream signaling output of FGFR2.
Reason: Duplicates IBA with different evidence. Core signaling function.
|
|
GO:0045595
regulation of cell differentiation
|
IEA
GO_REF:0000117 |
ACCEPT |
Summary: FGFR2 regulates differentiation of multiple cell types including osteoblasts, keratinocytes, and epithelial cells. This is a core function.
Reason: UniProt confirms role in "regulation of cell proliferation, differentiation, migration and apoptosis." Applies to both IIIb (epithelial differentiation) and IIIc (mesenchymal differentiation) isoforms.
|
|
GO:0048562
embryonic organ morphogenesis
|
IEA
GO_REF:0000117 |
ACCEPT |
Summary: FGFR2 is required for morphogenesis of multiple embryonic organs including limbs, lungs, and craniofacial structures. UniProt confirms it is "Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development."
Reason: Core developmental function. FGFR2 is essential for morphogenesis of multiple organs through epithelial-mesenchymal interactions. Consistent with ISS annotation for the same term.
Supporting Evidence:
UniProtKB:P21802
Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development
|
|
GO:0048705
skeletal system morphogenesis
|
IEA
GO_REF:0000117 |
ACCEPT |
Summary: FGFR2 is critical for skeletal development. Mutations cause multiple craniosynostosis syndromes (Crouzon, Apert, Pfeiffer, Jackson-Weiss).
Reason: UniProt confirms "required for normal skeleton development" and documents multiple skeletal disorder phenotypes from FGFR2 mutations.
|
|
GO:1904888
cranial skeletal system development
|
IEA
GO_REF:0000117 |
ACCEPT |
Summary: FGFR2 is critical for cranial skeleton development. Mutations cause craniosynostosis - premature fusion of cranial sutures.
Reason: Strong evidence from human genetics - FGFR2 mutations cause Crouzon syndrome, Apert syndrome, Pfeiffer syndrome, and other craniosynostoses.
|
|
GO:0005515
protein binding
|
IPI
PMID:10618369 Structural interactions of fibroblast growth factor receptor... |
MODIFY |
Summary: PMID:10618369 is a structural study of FGFR2-FGF1 complex. The term "protein binding" is uninformative - more specific terms like "fibroblast growth factor binding" are available and preferred.
Reason: "Protein binding" is too generic for GO annotation. This paper documents FGF binding which is already captured by GO:0017134.
Proposed replacements:
fibroblast growth factor binding
Supporting Evidence:
PMID:10618369
Structural interactions of fibroblast growth factor receptor with its ligands.
|
|
GO:0005515
protein binding
|
IPI
PMID:10830168 Crystal structures of two FGF-FGFR complexes reveal the dete... |
MODIFY |
Summary: PMID:10830168 reports crystal structures of FGF-FGFR complexes. Shows determinants of ligand-receptor specificity. "Protein binding" is too generic.
Reason: Paper specifically documents FGF binding. Should use GO:0017134 fibroblast growth factor binding instead.
Proposed replacements:
fibroblast growth factor binding
Supporting Evidence:
PMID:10830168
Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity.
|
|
GO:0005515
protein binding
|
IPI
PMID:11390973 Structural basis for fibroblast growth factor receptor 2 act... |
MODIFY |
Summary: PMID:11390973 describes structural basis for FGFR2 activation in Apert syndrome, examining FGF2 binding. "Protein binding" is too generic.
Reason: Paper documents FGF2 binding to FGFR2. Should use more specific term.
Proposed replacements:
fibroblast growth factor binding
Supporting Evidence:
PMID:11390973
Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome.
|
|
GO:0005515
protein binding
|
IPI
PMID:12591959 Structural basis by which alternative splicing confers speci... |
MODIFY |
Summary: PMID:12591959 examines structural basis by which alternative splicing confers specificity in FGF receptors. Shows FGF10 binding to FGFR2IIIb.
Reason: Paper documents isoform-specific FGF binding. Should use GO:0017134.
Proposed replacements:
fibroblast growth factor binding
Supporting Evidence:
PMID:12591959
Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors.
|
|
GO:0005515
protein binding
|
IPI
PMID:1309608 Determination of ligand-binding specificity by alternative s... |
MODIFY |
Summary: PMID:1309608 is a seminal paper showing that alternative splicing creates two distinct growth factor receptors with different ligand specificities. Documents FGF1 and FGF7 binding differences between isoforms.
Reason: Classic paper on FGFR2 isoform-specific FGF binding. Should use GO:0017134.
Proposed replacements:
fibroblast growth factor binding
Supporting Evidence:
PMID:1309608
Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene.
|
|
GO:0005515
protein binding
|
IPI
PMID:22726438 Inhibition of basal FGF receptor signaling by dimeric Grb2. |
MODIFY |
Summary: PMID:22726438 documents inhibition of basal FGF receptor signaling by dimeric Grb2. Shows GRB2 interaction with FGFR2.
Reason: Documents specific GRB2 binding. Should be annotated with a more specific term reflecting signaling adaptor interaction.
Proposed replacements:
transmembrane receptor protein tyrosine kinase adaptor activity
Supporting Evidence:
PMID:22726438
Inhibition of basal FGF receptor signaling by dimeric Grb2.
|
|
GO:0005515
protein binding
|
IPI
PMID:23597563 Molecular mechanism of SSR128129E, an extracellularly acting... |
MARK AS OVER ANNOTATED |
Summary: PMID:23597563 describes molecular mechanism of SSR128129E, an extracellularly acting small-molecule allosteric inhibitor. Documents drug-receptor interaction.
Reason: This paper is about drug binding, not protein-protein interaction. The "protein binding" annotation does not capture meaningful biology here.
Supporting Evidence:
PMID:23597563
Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling.
|
|
GO:0005515
protein binding
|
IPI
PMID:25241761 Using an in situ proximity ligation assay to systematically ... |
MARK AS OVER ANNOTATED |
Summary: PMID:25241761 uses in situ proximity ligation assay to profile endogenous protein-protein interactions. High-throughput interactome study.
Reason: High-throughput study without specific functional characterization. "Protein binding" is too generic to be informative.
Supporting Evidence:
PMID:25241761
Oct 9. Using an in situ proximity ligation assay to systematically profile endogenous protein-protein interactions in a pathway network.
|
|
GO:0005515
protein binding
|
IPI
PMID:26267536 Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for... |
MARK AS OVER ANNOTATED |
Summary: PMID:26267536 describes long-pentraxin 3 derivative as FGF trap for cancer therapy. Documents FGF sequestration rather than receptor binding.
Reason: Paper focuses on therapeutic FGF trapping, not native FGFR2 interactions. "Protein binding" is not informative here.
Supporting Evidence:
PMID:26267536
Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy.
|
|
GO:0005515
protein binding
|
IPI
PMID:33961781 Dual proteome-scale networks reveal cell-specific remodeling... |
MARK AS OVER ANNOTATED |
Summary: PMID:33961781 is a large-scale proteome study of the human interactome. High-throughput data without specific functional characterization.
Reason: High-throughput interactome study. "Protein binding" is too generic to be informative for specific gene annotation.
Supporting Evidence:
PMID:33961781
2021 May 6. Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.
|
|
GO:0005515
protein binding
|
IPI
PMID:35384245 Physical and functional interactome atlas of human receptor ... |
MARK AS OVER ANNOTATED |
Summary: PMID:35384245 is a physical interactome atlas of human receptor tyrosine kinases. Large-scale study of RTK interactions.
Reason: High-throughput interactome study. Generic "protein binding" annotations from such studies add little value.
Supporting Evidence:
PMID:35384245
Physical and functional interactome atlas of human receptor tyrosine kinases.
|
|
GO:0005515
protein binding
|
IPI
PMID:35922511 A physical wiring diagram for the human immune system. |
MARK AS OVER ANNOTATED |
Summary: PMID:35922511 is a physical wiring diagram for the human immune system. Large-scale protein interaction study.
Reason: High-throughput study. Generic "protein binding" from such studies is not informative for specific gene function.
Supporting Evidence:
PMID:35922511
Aug 3. A physical wiring diagram for the human immune system.
|
|
GO:0001837
epithelial to mesenchymal transition
|
IEA
GO_REF:0000107 |
KEEP AS NON CORE |
Summary: ISOFORM-SPECIFIC CONCERN: FGFR2 isoform switching (IIIb to IIIc) is associated with EMT. IIIb is epithelial; IIIc is mesenchymal. This annotation conflates gene-level with isoform-specific biology.
Reason: The isoform switch from IIIb to IIIc accompanies EMT in cancer, but FGFR2 itself does not directly cause EMT. This is a correlative rather than causative role. The annotation may be valid but represents secondary biology.
|
|
GO:0003416
endochondral bone growth
|
IEA
GO_REF:0000107 |
ACCEPT |
Summary: FGFR2 plays a role in bone development. Mutations cause craniosynostosis and affect skeletal growth.
Reason: Valid bone development function supported by disease phenotypes. UniProt documents FGFR2 role in osteogenesis and skeletal development.
|
|
GO:0009986
cell surface
|
IEA
GO_REF:0000107 |
ACCEPT |
Summary: FGFR2 is a cell surface receptor. More specific than plasma membrane in indicating the exposed surface.
Reason: Valid localization. FGFR2 is a transmembrane receptor exposed at the cell surface for ligand binding.
|
|
GO:0017134
fibroblast growth factor binding
|
IEA
GO_REF:0000120 |
ACCEPT |
Summary: Duplicate of IBA annotation. FGF binding is a core FGFR2 function.
Reason: Core function - duplicates IBA with different evidence.
|
|
GO:0032496
response to lipopolysaccharide
|
IEA
GO_REF:0000107 |
MARK AS OVER ANNOTATED |
Summary: LPS response is not a characterized FGFR2 function. This annotation may reflect expression changes rather than direct function.
Reason: No clear evidence that FGFR2 has a direct role in LPS response. This is likely an ortholog transfer from expression data rather than functional data.
|
|
GO:0044344
cellular response to fibroblast growth factor stimulus
|
IEA
GO_REF:0000107 |
ACCEPT |
Summary: FGFR2 mediates cellular response to FGF. This is its core function as an FGF receptor.
Reason: Core function. FGFR2 is the receptor that mediates cellular response to multiple FGFs.
|
|
GO:0045471
response to ethanol
|
IEA
GO_REF:0000107 |
MARK AS OVER ANNOTATED |
Summary: Ethanol response is not a characterized FGFR2 function. This annotation likely reflects expression changes rather than direct function.
Reason: No evidence that FGFR2 has a direct role in ethanol response. Likely ortholog transfer from expression data.
|
|
GO:0048333
mesodermal cell differentiation
|
IEA
GO_REF:0000107 |
ACCEPT |
Summary: FGFR2IIIc (mesenchymal isoform) is involved in mesenchymal/mesodermal cell biology. This annotation may be partially isoform-specific.
Reason: Valid for FGFR2IIIc isoform specifically. FGF signaling through IIIc supports mesenchymal cell differentiation.
|
|
GO:0050680
negative regulation of epithelial cell proliferation
|
IEA
GO_REF:0000120 |
UNDECIDED |
Summary: This annotation seems contradictory to FGFR2's known role in promoting keratinocyte (epithelial) proliferation. The annotation may be context- specific or erroneous.
Reason: UniProt states FGFR2 "promotes cell proliferation in keratinocytes" which contradicts negative regulation. May apply to specific contexts but unclear.
|
|
GO:0071300
cellular response to retinoic acid
|
IEA
GO_REF:0000107 |
MARK AS OVER ANNOTATED |
Summary: Retinoic acid response is not a characterized FGFR2 function. May reflect expression regulation rather than functional response.
Reason: No clear evidence for direct FGFR2 role in retinoic acid response. Likely ortholog transfer from expression data.
|
|
GO:0071456
cellular response to hypoxia
|
IEA
GO_REF:0000107 |
MARK AS OVER ANNOTATED |
Summary: Hypoxia response is not a well-characterized FGFR2 function. May reflect expression changes in hypoxia.
Reason: No clear evidence for direct FGFR2 role in hypoxia response. Likely ortholog transfer from expression data.
|
|
GO:0071560
cellular response to transforming growth factor beta stimulus
|
IEA
GO_REF:0000107 |
KEEP AS NON CORE |
Summary: TGF-beta response may involve FGFR2 in certain contexts, especially related to EMT where both pathways interact.
Reason: There is crosstalk between FGF and TGF-beta pathways in EMT and development, but this is not a primary FGFR2 function.
|
|
GO:1904707
positive regulation of vascular associated smooth muscle cell proliferation
|
IEA
GO_REF:0000107 |
KEEP AS NON CORE |
Summary: FGF signaling can promote smooth muscle cell proliferation, potentially via FGFR2IIIc in mesenchymal cells.
Reason: Valid but not a primary FGFR2 function. FGF2 signaling through FGFR can promote VSMC proliferation but this is not unique to FGFR2.
|
|
GO:0009986
cell surface
|
IDA
PMID:17959718 Heparanase cleavage of perlecan heparan sulfate modulates FG... |
ACCEPT |
Summary: PMID:17959718 examines heparanase cleavage of perlecan and FGF10 activity in submandibular gland branching morphogenesis. Shows FGFR2 at cell surface.
Reason: Direct experimental evidence for cell surface localization during FGF10-FGFR2 signaling in branching morphogenesis.
Supporting Evidence:
PMID:17959718
Heparanase cleavage of perlecan heparan sulfate modulates FGF10 activity during ex vivo submandibular gland branching morphogenesis.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654748 |
ACCEPT |
Summary: Reactome pathway annotation. Multiple Reactome entries document FGFR2 plasma membrane localization in various signaling contexts.
Reason: Plasma membrane localization is well established for transmembrane FGFR2 isoforms. Reactome pathway data supports this.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5655233 |
ACCEPT |
Summary: Reactome pathway annotation for FGFR2 signaling. Duplicates other PM annotations.
Reason: Valid localization, consistent with other evidence.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5655241 |
ACCEPT |
Summary: Reactome pathway annotation. Part of FGFR2 signaling pathway documentation.
Reason: Valid localization, consistent with other evidence.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5655245 |
ACCEPT |
Summary: Reactome pathway annotation for FGFR2 at plasma membrane.
Reason: Valid localization, duplicates other evidence.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5655268 |
ACCEPT |
Summary: Reactome pathway annotation for FGFR2 signaling.
Reason: Valid localization, consistent with established biology.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5655301 |
ACCEPT |
Summary: Reactome pathway annotation for FGFR2 signaling.
Reason: Valid localization.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5655320 |
ACCEPT |
Summary: Reactome pathway annotation for FGFR2 signaling.
Reason: Valid localization.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5655323 |
ACCEPT |
Summary: Reactome pathway annotation for FGFR2 signaling.
Reason: Valid localization.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5655339 |
ACCEPT |
Summary: Reactome pathway annotation for FGFR2 signaling.
Reason: Valid localization.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5655343 |
ACCEPT |
Summary: Reactome pathway annotation for FGFR2 signaling.
Reason: Valid localization.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-8853313 |
ACCEPT |
Summary: Reactome pathway annotation for FGFR2 fusions autophosphorylation. Documents aberrant signaling in cancer.
Reason: Valid localization for wild-type and fusion FGFR2.
|
|
GO:0010839
negative regulation of keratinocyte proliferation
|
IMP
PMID:21412257 MiR-125b, a microRNA downregulated in psoriasis, modulates k... |
REMOVE |
Summary: PMID:21412257 shows miR-125b modulates keratinocyte proliferation by targeting FGFR2. Knockdown of FGFR2 by miRNA reduces proliferation, suggesting FGFR2 normally promotes (not inhibits) keratinocyte proliferation.
Reason: This annotation appears incorrect. The paper shows that FGFR2 knockdown reduces keratinocyte proliferation, meaning FGFR2 positively regulates proliferation. The annotation should be GO:0050679 (positive regulation of epithelial cell proliferation) rather than negative regulation.
Supporting Evidence:
PMID:21412257
Mar 17. MiR-125b, a microRNA downregulated in psoriasis, modulates keratinocyte proliferation by targeting FGFR2.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-8853319 |
ACCEPT |
Summary: Reactome pathway annotation for plasma membrane localization. FGFR2 transmembrane isoforms are plasma membrane receptors. Multiple Reactome pathways include FGFR2 at the plasma membrane.
Reason: Correct localization for transmembrane FGFR2 isoforms. Duplicate entries from different Reactome pathways reflect FGFR2 participation in multiple signaling contexts at the plasma membrane.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-2029989 |
ACCEPT |
Summary: Reactome pathway annotation duplicate. Plasma membrane localization is well established for transmembrane FGFR2 isoforms.
Reason: Duplicate of other plasma membrane annotations from different Reactome pathway contexts. Valid for transmembrane isoforms.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-2029983 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-2029984 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-2033472 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-2033474 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-2033479 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-2033486 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-2033488 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-2033490 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-2077424 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-109699 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-190413 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-2316434 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-2400009 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654147 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654157 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654159 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654397 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654399 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654402 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654404 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654406 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654407 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654562 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654603 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654605 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654607 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654608 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654612 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654614 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654615 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654618 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654620 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654622 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654677 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654697 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654701 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5654729 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-5672965 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-190258 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-190260 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-190408 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-NUL-8853328 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-2029988 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-2029992 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0005886
plasma membrane
|
TAS
Reactome:R-HSA-2067713 |
ACCEPT |
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
|
|
GO:0048701
embryonic cranial skeleton morphogenesis
|
IMP
PMID:7874170 Jackson-Weiss and Crouzon syndromes are allelic with mutatio... |
ACCEPT |
Summary: Mutations in FGFR2 cause Jackson-Weiss and Crouzon syndromes, which feature craniosynostosis (premature fusion of cranial sutures). This demonstrates FGFR2 role in cranial skeleton development. PMID:7874170 identified FGFR2 mutations in the IIIc domain in Jackson-Weiss syndrome families.
Reason: Strong genetic evidence linking FGFR2 mutations to craniosynostosis syndromes. FGFR2 is essential for normal cranial suture development; gain-of-function mutations cause premature suture fusion. This is a well-established core developmental function particularly for the IIIc isoform in mesenchyme.
Supporting Evidence:
PMID:7874170
We now report an FGFR2 mutation in the conserved region of the immunoglobulin IIIc domain in the Jackson-Weiss syndrome family in which the syndrome was originally described.
|
|
GO:0048701
embryonic cranial skeleton morphogenesis
|
IMP
PMID:7987400 Mutations in the fibroblast growth factor receptor 2 gene ca... |
ACCEPT |
Summary: PMID:7987400 demonstrates that mutations in FGFR2 cause Crouzon syndrome, providing additional genetic evidence for FGFR2 role in cranial skeleton development. Multiple mutations in the B exon (IIIc domain) were identified.
Reason: Complements PMID:7874170 evidence. Crouzon syndrome is autosomal dominant craniosynostosis caused by FGFR2 mutations, including cysteine substitutions in the Ig-like domain. Core developmental function.
Supporting Evidence:
PMID:7987400
We now present evidence that mutations in the fibroblast growth factor receptor 2 gene (FGFR2) cause Crouzon syndrome.
|
|
GO:0005634
nucleus
|
IDA
PMID:16597614 FGF-10 and its receptor exhibit bidirectional paracrine targ... |
KEEP AS NON CORE |
Summary: PMID:16597614 observed FGF-10 receptor (FGFR2IIIb/KGFR) in nucleus of urothelial cells by microscopy. This is an intriguing finding suggesting nuclear translocation of activated receptor, though unconventional.
Reason: Nuclear localization of FGFRs has been reported but is non-canonical and represents a specialized signaling mechanism rather than the primary localization. The main function of FGFR2 is at the plasma membrane.
Supporting Evidence:
PMID:16597614
Deconvolution, light and transmission electron microscopic studies captured FGF-10 and its receptor in association with the urothelial cell surface, in cytoplasm, and within nuclei
|
|
GO:0005737
cytoplasm
|
IDA
PMID:16597614 FGF-10 and its receptor exhibit bidirectional paracrine targ... |
ACCEPT |
Summary: PMID:16597614 showed FGFR2 (FGF-10 receptor) localizes to cytoplasm during its trafficking and signaling in urothelial cells.
Reason: FGFR2 is found in cytoplasm during biosynthesis, trafficking to plasma membrane, and after receptor internalization. Valid localization.
Supporting Evidence:
PMID:16597614
Deconvolution, light and transmission electron microscopic studies captured FGF-10 and its receptor in association with the urothelial cell surface, in cytoplasm, and within nuclei
|
|
GO:0009986
cell surface
|
IDA
PMID:16597614 FGF-10 and its receptor exhibit bidirectional paracrine targ... |
ACCEPT |
Summary: PMID:16597614 localized FGFR2 (FGF-10 receptor) to the urothelial cell surface, consistent with its function as a transmembrane receptor.
Reason: Cell surface localization is expected for transmembrane receptor tyrosine kinases. This is functionally equivalent to plasma membrane localization.
Supporting Evidence:
PMID:16597614
Deconvolution, light and transmission electron microscopic studies captured FGF-10 and its receptor in association with the urothelial cell surface
|
|
GO:0005007
fibroblast growth factor receptor activity
|
IDA
PMID:15629145 Tyrosine 769 of the keratinocyte growth factor receptor is r... |
ACCEPT |
Summary: PMID:15629145 studied KGFR (FGFR2IIIb) signaling through autophosphorylation and downstream pathway activation. The study demonstrated functional FGF receptor activity through tyrosine phosphorylation assays.
Reason: Direct experimental demonstration of FGFR2 (KGFR isoform) receptor activity including autophosphorylation and signaling. Core molecular function.
Supporting Evidence:
PMID:15629145
KGFR is rapidly autophosphorylated on specific tyrosine residues in the intracellular domain, recruits substrate proteins
|
|
GO:0005007
fibroblast growth factor receptor activity
|
IDA
PMID:8663044 Receptor specificity of the fibroblast growth factor family. |
ACCEPT |
Summary: PMID:8663044 systematically tested FGF receptor splice variants for ligand specificity and mitogenic activity. This landmark study established FGFR2 isoform-specific ligand binding and receptor activation.
Reason: Comprehensive biochemical characterization of FGFR2 splice variants as functional FGF receptors. Demonstrated mitogenic activity with multiple FGF ligands. Foundational study for FGFR2 biology.
Supporting Evidence:
PMID:8663044
we have engineered mitogenically responsive cell lines expressing the major splice variants of all the known FGF receptors. We have assayed the mitogenic activity of the nine known FGF ligands on these cell lines.
|
|
GO:0005886
plasma membrane
|
IDA
PMID:15629145 Tyrosine 769 of the keratinocyte growth factor receptor is r... |
ACCEPT |
Summary: PMID:15629145 studied KGFR (FGFR2IIIb) at the plasma membrane where it undergoes ligand-induced internalization.
Reason: Plasma membrane localization is the primary site of FGFR2 function as a transmembrane receptor.
Supporting Evidence:
PMID:15629145
Tyrosine 769 of the keratinocyte growth factor receptor is required for receptor signaling but not endocytosis.
|
|
GO:0005886
plasma membrane
|
IDA
PMID:16844695 Intracellular retention, degradation, and signaling of glyco... |
ACCEPT |
Summary: PMID:16844695 studied FGFR2 trafficking and localization, showing wild-type FGFR2 localizes to plasma membrane while glycosylation-deficient and mutant forms show altered localization.
Reason: Demonstrates plasma membrane is the normal localization for properly processed FGFR2, while mutations affecting glycosylation impair trafficking.
Supporting Evidence:
PMID:16844695
we show that trafficking and autoactivation of wild type FGFR2 is glycosylation-dependent
|
|
GO:0008284
positive regulation of cell population proliferation
|
IMP
PMID:15629145 Tyrosine 769 of the keratinocyte growth factor receptor is r... |
ACCEPT |
Summary: PMID:15629145 showed that KGFR Y769F mutation impairs cell proliferation, demonstrating that functional KGFR (FGFR2IIIb) signaling promotes proliferation.
Reason: Mutant phenotype analysis demonstrates FGFR2 promotes cell proliferation. Core biological process for FGFR signaling.
Supporting Evidence:
PMID:15629145
tyrosine 769 is required...for cell proliferation through the regulation of FRS2 tyrosine phosphorylation
|
|
GO:0008284
positive regulation of cell population proliferation
|
IDA
PMID:8663044 Receptor specificity of the fibroblast growth factor family. |
ACCEPT |
Summary: PMID:8663044 used mitogenic assays to demonstrate FGF-induced proliferation through FGFR2. Multiple FGF ligands activated FGFR2-expressing cells.
Reason: Direct mitogenic assays showing FGFR2 activation promotes cell proliferation. Foundational evidence for this core biological process.
Supporting Evidence:
PMID:8663044
Receptor specificity of the fibroblast growth factor family.
|
|
GO:0008543
fibroblast growth factor receptor signaling pathway
|
IDA
PMID:15629145 Tyrosine 769 of the keratinocyte growth factor receptor is r... |
ACCEPT |
Summary: PMID:15629145 characterized KGFR signaling pathway including PLCgamma recruitment, FRS2 phosphorylation, and MAPK activation. This directly demonstrates FGF receptor signaling.
Reason: Detailed characterization of FGFR2 (KGFR) signaling pathway components. Core biological process.
Supporting Evidence:
PMID:15629145
tyrosine 769 is required for the binding to KGFR and tyrosine phosphorylation of PLCgamma as well as for the full activation of MAPKs
|
|
GO:0008543
fibroblast growth factor receptor signaling pathway
|
IDA
PMID:8663044 Receptor specificity of the fibroblast growth factor family. |
ACCEPT |
Summary: PMID:8663044 demonstrated FGF signaling through FGFR2 using mitogenic assays as readout of pathway activation.
Reason: Functional demonstration of FGF signaling pathway activation through FGFR2.
Supporting Evidence:
PMID:8663044
Receptor specificity of the fibroblast growth factor family.
|
|
GO:0010518
positive regulation of phospholipase activity
|
IMP
PMID:16844695 Intracellular retention, degradation, and signaling of glyco... |
ACCEPT |
Summary: PMID:16844695 showed both wild-type and mutant FGFR2 signal through PLCgamma. The C278F mutation and unglycosylated FGFR2 signal through PLCgamma in a ligand-independent manner.
Reason: Demonstrates FGFR2 activates PLCgamma (phospholipase C gamma), which is a well-established downstream effector of FGFR signaling.
Supporting Evidence:
PMID:16844695
Both FGFR2C278F and unglycosylated wild type FGFR2 signal through phospholipase Cgamma in a ligand-independent manner
|
|
GO:0017134
fibroblast growth factor binding
|
IDA
PMID:8663044 Receptor specificity of the fibroblast growth factor family. |
ACCEPT |
Summary: PMID:8663044 systematically characterized FGF binding specificity of FGFR2 splice variants. FGF1 binds all variants; FGF2 binds IIIc; FGF7 binds IIIb.
Reason: Comprehensive biochemical characterization of FGF binding to FGFR2 isoforms. Core molecular function. Established isoform-specific ligand preferences.
Supporting Evidence:
PMID:8663044
FGF 1 is the only FGF that can activate all FGF receptor splice variants
|
|
GO:0018108
peptidyl-tyrosine phosphorylation
|
IDA
PMID:15629145 Tyrosine 769 of the keratinocyte growth factor receptor is r... |
ACCEPT |
Summary: PMID:15629145 demonstrated KGFR (FGFR2IIIb) phosphorylates tyrosine residues on PLCgamma and FRS2 substrates. The study showed Y769 is required for PLCgamma and FRS2 tyrosine phosphorylation.
Reason: Direct demonstration of FGFR2 tyrosine kinase activity phosphorylating substrates. Core enzymatic function of receptor tyrosine kinases.
Supporting Evidence:
PMID:15629145
tyrosine 769 is required for the binding to KGFR and tyrosine phosphorylation of PLCgamma...through the regulation of FRS2 tyrosine phosphorylation
|
|
GO:0018108
peptidyl-tyrosine phosphorylation
|
IDA
PMID:16844695 Intracellular retention, degradation, and signaling of glyco... |
ACCEPT |
Summary: PMID:16844695 showed FGFR2 phosphorylates itself and downstream substrates. Both wild-type and mutant FGFR2 exhibit tyrosine phosphorylation activity.
Reason: Confirms FGFR2 tyrosine kinase activity in phosphorylating substrates.
Supporting Evidence:
PMID:16844695
2006 Jul 14. Intracellular retention, degradation, and signaling of glycosylation-deficient FGFR2 and craniosynostosis syndrome-associated FGFR2C278F.
|
|
GO:0033688
regulation of osteoblast proliferation
|
TAS
PMID:15190072 Cbl-mediated degradation of Lyn and Fyn induced by constitut... |
ACCEPT |
Summary: PMID:15190072 studied FGFR2 S252W gain-of-function mutation in osteoblasts. The study shows constitutive FGFR2 activation affects osteoblast proliferation through regulation of Src family kinases Lyn and Fyn.
Reason: Direct evidence that FGFR2 regulates osteoblast proliferation. This function is highly relevant to craniosynostosis syndromes caused by FGFR2 mutations.
Supporting Evidence:
PMID:15190072
Fibroblast growth factors (FGFs) play an important regulatory role in skeletal development and bone formation
|
|
GO:0042803
protein homodimerization activity
|
IPI
PMID:16844695 Intracellular retention, degradation, and signaling of glyco... |
ACCEPT |
Summary: PMID:16844695 studied FGFR2 homodimerization which is required for receptor activation. FGFR2 dimerizes upon ligand binding or constitutively in gain-of-function mutants.
Reason: FGFR2 homodimerization is essential for receptor activation. Documented by immunoprecipitation studies. Core mechanism of receptor activation.
Supporting Evidence:
PMID:16844695
2006 Jul 14. Intracellular retention, degradation, and signaling of glycosylation-deficient FGFR2 and craniosynostosis syndrome-associated FGFR2C278F.
|
|
GO:0043410
positive regulation of MAPK cascade
|
IMP
PMID:15629145 Tyrosine 769 of the keratinocyte growth factor receptor is r... |
ACCEPT |
Summary: PMID:15629145 showed that KGFR Y769F mutation impairs MAPK activation, demonstrating that functional FGFR2 signaling is required for full MAPK cascade activation.
Reason: Mutant phenotype analysis confirms FGFR2 activates MAPK cascade. Core downstream signaling pathway.
Supporting Evidence:
PMID:15629145
tyrosine 769 is required...for the full activation of MAPKs
|
|
GO:0045667
regulation of osteoblast differentiation
|
TAS
PMID:15190072 Cbl-mediated degradation of Lyn and Fyn induced by constitut... |
ACCEPT |
Summary: PMID:15190072 demonstrated that constitutive FGFR2 activation promotes osteoblast differentiation through Cbl-mediated degradation of Src family kinases Lyn and Fyn.
Reason: Direct evidence that FGFR2 regulates osteoblast differentiation. The FGFR2 S252W mutation (Apert syndrome) increases ALP expression, a marker of osteoblast differentiation.
Supporting Evidence:
PMID:15190072
constitutive FGFR2 activation induces c-Cbl-dependent Lyn and Fyn proteasome degradation, resulting in...increased ALP expression
|
|
GO:0046777
protein autophosphorylation
|
IDA
PMID:15629145 Tyrosine 769 of the keratinocyte growth factor receptor is r... |
ACCEPT |
Summary: PMID:15629145 demonstrated KGFR (FGFR2IIIb) autophosphorylation on tyrosine residues including Y769 upon ligand binding.
Reason: Direct demonstration of FGFR2 autophosphorylation. Core mechanism of receptor tyrosine kinase activation.
Supporting Evidence:
PMID:15629145
KGFR is rapidly autophosphorylated on specific tyrosine residues in the intracellular domain
|
|
GO:0048705
skeletal system morphogenesis
|
TAS
PMID:15190072 Cbl-mediated degradation of Lyn and Fyn induced by constitut... |
ACCEPT |
Summary: PMID:15190072 discusses FGFR2 role in skeletal development. FGFR2 mutations cause skeletal abnormalities including craniosynostosis.
Reason: FGFR2 is essential for skeletal system development. Mutations cause multiple craniosynostosis syndromes affecting skull development.
Supporting Evidence:
PMID:15190072
Fibroblast growth factors (FGFs) play an important regulatory role in skeletal development and bone formation
|
|
GO:0035602
fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow cell
|
ISS
GO_REF:0000024 |
MARK AS OVER ANNOTATED |
Summary: ISS annotation transferred from mouse ortholog. Overly specific term for a context-dependent function that is not a primary role for human FGFR2.
Reason: While FGF signaling can have anti-apoptotic effects, this highly specific term (bone marrow cell apoptosis) is not a core function of human FGFR2. Mouse knockout data may not directly translate to primary human function.
|
|
GO:0035603
fibroblast growth factor receptor signaling pathway involved in hemopoiesis
|
ISS
GO_REF:0000024 |
MARK AS OVER ANNOTATED |
Summary: ISS annotation transferred from mouse ortholog. Hemopoiesis is not a primary function of FGFR2; this likely reflects pleiotropic effects in mouse models.
Reason: FGFR2 primary functions are in epithelial-mesenchymal signaling, skeletal development, and wound healing. Hemopoietic role is not a core function.
|
|
GO:0035604
fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow
|
ISS
GO_REF:0000024 |
MARK AS OVER ANNOTATED |
Summary: ISS annotation transferred from mouse ortholog. Overly specific term for bone marrow context that is not a primary FGFR2 function.
Reason: While FGFR2 promotes proliferation generally, this bone marrow-specific context is not a core function for human FGFR2.
|
|
GO:0035607
fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog. FGFR2 has roles in brain development but this specific term for orbitofrontal cortex is highly specialized.
Reason: Brain development role is plausible given FGFR2 mutations cause Crouzon and Apert syndromes which can have CNS effects. However, this is a very specific developmental context, not a core function.
|
|
GO:0021769
orbitofrontal cortex development
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog for orbitofrontal cortex development. Related to the above signaling pathway annotation.
Reason: Specialized developmental context. FGFR2 contributes to brain development but this specific region is not a core function.
|
|
GO:0021847
ventricular zone neuroblast division
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog for neural progenitor division in the ventricular zone during brain development.
Reason: FGF signaling has roles in neural development but this is a specialized developmental function, not a core FGFR2 function.
|
|
GO:0021860
pyramidal neuron development
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog for pyramidal neuron development.
Reason: Specialized neuronal development context. Not a primary FGFR2 function.
|
|
GO:0045787
positive regulation of cell cycle
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2 promotes cell proliferation which involves positive regulation of the cell cycle.
Reason: Consistent with FGFR2 role in promoting cell proliferation. Mitogenic signaling through FRS2/MAPK pathway drives cell cycle progression.
|
|
GO:0060076
excitatory synapse
|
ISS
GO_REF:0000024 |
MARK AS OVER ANNOTATED |
Summary: ISS annotation from mouse ortholog suggesting FGFR2 localization at excitatory synapses. Unusual localization for a growth factor receptor.
Reason: Synaptic localization is not a core function of FGFR2. May reflect specialized neuronal signaling in mouse models but not a primary human FGFR2 function.
|
|
GO:0000122
negative regulation of transcription by RNA polymerase II
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog. Indirect effect of FGFR2 signaling on transcription through downstream pathways.
Reason: FGFR2 signaling can affect transcription through MAPK and other pathways, but transcriptional regulation is an indirect downstream effect, not a core molecular function of the receptor.
|
|
GO:0001525
angiogenesis
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog. Duplicate of IBA annotation - FGF signaling has documented roles in angiogenesis.
Reason: Consistent with IBA annotation. Angiogenesis is a documented but non-core function for FGFR2; FGFR1 may be more prominent in vascular biology.
|
|
GO:0001657
ureteric bud development
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog. FGFR2 has roles in kidney development including ureteric bud branching morphogenesis.
Reason: UniProt notes FGFR2 is required for normal embryonic patterning including organogenesis. Kidney development is a documented but tissue-specific developmental function.
|
|
GO:0001701
in utero embryonic development
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog. FGFR2 is required for normal embryonic development as evidenced by embryonic lethality in knockout mice.
Reason: Very broad developmental term. FGFR2 is essential for development but more specific terms (limb, lung, skeletal) better capture core functions.
|
|
GO:0002053
positive regulation of mesenchymal cell proliferation
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2IIIc (mesenchymal isoform) promotes mesenchymal cell proliferation in response to FGF2/4 from epithelium.
Reason: Core function for FGFR2IIIc isoform. Mesenchymal proliferation is central to epithelial-mesenchymal signaling that FGFR2 mediates in development.
|
|
GO:0003148
outflow tract septum morphogenesis
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog. Cardiac outflow tract development involves FGFR signaling but is a specialized developmental context.
Reason: Cardiac development role is documented for FGFRs but this specific structure is not a core FGFR2 function.
|
|
GO:0003149
membranous septum morphogenesis
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog. Cardiac septum development is a specialized developmental context.
Reason: Specialized cardiac developmental function, not a core FGFR2 function.
|
|
GO:0007267
cell-cell signaling
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2 mediates paracrine signaling between epithelium and mesenchyme.
Reason: Core function. FGFR2 mediates paracrine FGF signaling between cell types, particularly epithelial-mesenchymal communication where IIIb receives signals from mesenchyme and IIIc receives signals from epithelium.
|
|
GO:0007409
axonogenesis
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog. FGF signaling has roles in axon guidance and neuronal development.
Reason: Neural development role is documented but not a primary FGFR2 function. More specialized than core epithelial-mesenchymal signaling roles.
|
|
GO:0008589
regulation of smoothened signaling pathway
|
ISS
GO_REF:0000024 |
MARK AS OVER ANNOTATED |
Summary: ISS annotation from mouse ortholog. Cross-talk between FGF and Hedgehog (Smoothened) pathways has been reported in development.
Reason: While pathway cross-talk exists, direct regulation of Smoothened signaling is not a core FGFR2 function. This represents indirect developmental pathway interactions rather than a primary function.
|
|
GO:0009791
post-embryonic development
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog. FGFR2 has roles in tissue homeostasis and repair after embryonic development.
Reason: FGFR2 continues to function in adult tissue homeostasis and wound healing but this is a broad term. Embryonic roles are better documented.
|
|
GO:0009880
embryonic pattern specification
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2 contributes to embryonic patterning through epithelial-mesenchymal interactions.
Reason: UniProt confirms FGFR2 is required for normal embryonic patterning. FGF signaling through FGFR2 establishes tissue boundaries and patterns during development.
|
|
GO:0009887
animal organ morphogenesis
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2 is required for morphogenesis of multiple organs including limbs, lungs, and skeleton.
Reason: Core developmental function. FGFR2 is essential for branching morphogenesis and organ development, particularly lungs, limbs, and craniofacial skeleton.
|
|
GO:0016331
morphogenesis of embryonic epithelium
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2IIIb is expressed in epithelium and receives signals from mesenchyme to direct epithelial morphogenesis.
Reason: Core function for FGFR2IIIb isoform. Epithelial morphogenesis through FGF7/10 signaling is a primary developmental role.
|
|
GO:0022612
gland morphogenesis
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2 is required for salivary gland, lacrimal gland, and other gland development through branching morphogenesis.
Reason: Core developmental function. FGFR2-mediated branching morphogenesis is essential for gland development in multiple organ systems.
|
|
GO:0030177
positive regulation of Wnt signaling pathway
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog. Cross-talk between FGF and Wnt pathways occurs during development but this is indirect signaling.
Reason: FGF-Wnt pathway interactions exist during development but positive regulation of Wnt signaling is not a direct core function of FGFR2.
|
|
GO:0030282
bone mineralization
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog. FGFR2 regulates osteoblast differentiation and bone development; mineralization is a downstream effect.
Reason: Indirect effect of FGFR2 on osteoblast function. The core function is regulating osteoblast proliferation/differentiation rather than mineralization per se.
|
|
GO:0030324
lung development
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2 is essential for lung branching morphogenesis. UniProt confirms role in lung morphogenesis.
Reason: Core developmental function. FGFR2 (particularly IIIb/KGFR) is essential for lung epithelial branching morphogenesis through FGF10 signaling.
|
|
GO:0030855
epithelial cell differentiation
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2IIIb in epithelial cells regulates their differentiation in response to mesenchymal FGF signals.
Reason: Core function for FGFR2IIIb isoform. Epithelial differentiation is directed by FGF7/10 signaling through the epithelial FGFR2 isoform.
|
|
GO:0030901
midbrain development
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog for midbrain development.
Reason: Brain development is one of many developmental contexts where FGFR2 functions, but not a primary function.
|
|
GO:0030916
otic vesicle formation
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog for inner ear development.
Reason: Specialized developmental context. FGFR2 contributes to ear development but this is not a core function.
|
|
GO:0031069
hair follicle morphogenesis
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2 is required for skin development including hair follicles. UniProt notes role in skin development.
Reason: Documented role in skin development. FGF signaling through FGFR2IIIb contributes to epithelial appendage formation including hair follicles.
|
|
GO:0032808
lacrimal gland development
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog. Lacrimal gland develops through branching morphogenesis requiring FGFR2 signaling.
Reason: Example of gland morphogenesis role. More general gland morphogenesis term already captures this function.
|
|
GO:0035265
organ growth
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2 promotes cell proliferation which contributes to organ growth during development.
Reason: General term consistent with FGFR2 role in promoting proliferation during organ development.
|
|
GO:0042472
inner ear morphogenesis
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog for inner ear development.
Reason: Specialized developmental context for ear morphogenesis.
|
|
GO:0042476
odontogenesis
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog. FGF signaling is involved in tooth development through epithelial-mesenchymal interactions.
Reason: Tooth development involves FGFR2 but is a specialized developmental context rather than a core function.
|
|
GO:0045165
cell fate commitment
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog. FGFR2 signaling influences cell fate decisions during development.
Reason: Broad developmental term. FGFR2 influences cell fate but more specific terms better capture its functions.
|
|
GO:0045944
positive regulation of transcription by RNA polymerase II
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog. FGFR2 signaling can activate transcription through MAPK pathway and transcription factors.
Reason: Indirect downstream effect of FGFR2 signaling rather than a core molecular function of the receptor.
|
|
GO:0048286
lung alveolus development
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. Specific aspect of lung development where FGFR2 contributes to alveolar formation.
Reason: Part of core lung development function. FGFR2 is essential for lung morphogenesis including alveolar development.
|
|
GO:0048557
embryonic digestive tract morphogenesis
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog for GI tract development.
Reason: One of many organs where FGFR2 contributes to development but not a primary documented function.
|
|
GO:0048562
embryonic organ morphogenesis
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. General term for FGFR2 role in organ development during embryogenesis.
Reason: Core developmental function. FGFR2 is essential for morphogenesis of multiple organs through epithelial-mesenchymal interactions.
|
|
GO:0048565
digestive tract development
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog for GI tract development.
Reason: Digestive tract development is one of many developmental contexts.
|
|
GO:0048568
embryonic organ development
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. Broad term for embryonic organogenesis role of FGFR2.
Reason: Core developmental function consistent with FGFR2 role in multiple organ systems during development.
|
|
GO:0048608
reproductive structure development
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog for reproductive organ development.
Reason: Specialized developmental context not emphasized in human FGFR2 function.
|
|
GO:0048730
epidermis morphogenesis
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2 is required for skin development. UniProt confirms role in skin development.
Reason: Documented function. FGFR2IIIb in keratinocytes responds to FGF7/KGF from dermal fibroblasts to regulate epidermis.
|
|
GO:0048755
branching morphogenesis of a nerve
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog for nerve branching.
Reason: Specialized neural context not a primary FGFR2 function.
|
|
GO:0048762
mesenchymal cell differentiation
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2IIIc in mesenchyme responds to epithelial FGFs to promote mesenchymal differentiation.
Reason: Core function for FGFR2IIIc isoform. Mesenchymal differentiation is central to FGFR2 role in development.
|
|
GO:0050679
positive regulation of epithelial cell proliferation
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2IIIb promotes epithelial cell proliferation in response to FGF7/10. UniProt confirms proliferation in keratinocytes.
Reason: Core function for FGFR2IIIb isoform. Epithelial proliferation is a primary response to FGF7/10 signaling.
|
|
GO:0051150
regulation of smooth muscle cell differentiation
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog for smooth muscle differentiation.
Reason: Specialized context for FGFR2 function in mesenchymal differentiation.
|
|
GO:0051781
positive regulation of cell division
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2 promotes cell proliferation which involves cell division.
Reason: Consistent with core mitogenic function of FGFR2 signaling.
|
|
GO:0055010
ventricular cardiac muscle tissue morphogenesis
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog for cardiac development.
Reason: Cardiac development context is not a primary FGFR2 function.
|
|
GO:0060045
positive regulation of cardiac muscle cell proliferation
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog for cardiac muscle proliferation.
Reason: Specialized cardiac context not a primary FGFR2 function.
|
|
GO:0060174
limb bud formation
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2 is essential for limb bud development. UniProt confirms role in limb bud development.
Reason: Core developmental function. FGFR2 is required for limb bud outgrowth and patterning through FGF signaling.
|
|
GO:0060348
bone development
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2 is essential for bone development; mutations cause craniosynostosis syndromes.
Reason: Core developmental function. FGFR2 mutations in humans cause multiple skeletal syndromes demonstrating essential role in osteogenesis.
|
|
GO:0060349
bone morphogenesis
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2 regulates bone shape through effects on osteoblast function.
Reason: Core function evidenced by craniosynostosis syndromes where FGFR2 mutations cause abnormal skull bone morphology.
|
|
GO:0060442
branching involved in prostate gland morphogenesis
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog. Prostate gland develops through branching morphogenesis involving FGFR2.
Reason: Specific example of branching morphogenesis. General gland morphogenesis term captures this function.
|
|
GO:0060445
branching involved in salivary gland morphogenesis
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. Salivary gland develops through FGFR2-dependent branching morphogenesis.
Reason: Well-documented example of FGFR2-dependent branching morphogenesis. FGF10/FGFR2IIIb signaling is essential for salivary gland development.
|
|
GO:0060449
bud elongation involved in lung branching
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. Specific aspect of lung branching morphogenesis involving bud outgrowth.
Reason: Core lung development function. FGF10/FGFR2IIIb signaling drives epithelial bud elongation in lung branching.
|
|
GO:0060463
lung lobe morphogenesis
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog for lung lobe formation.
Reason: Part of core lung development function of FGFR2.
|
|
GO:0060484
lung-associated mesenchyme development
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2IIIc in lung mesenchyme responds to epithelial FGFs during development.
Reason: Core lung development function. Both epithelial (IIIb) and mesenchymal (IIIc) FGFR2 isoforms contribute to lung development.
|
|
GO:0060501
positive regulation of epithelial cell proliferation involved in lung morphogenesis
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGF10/FGFR2IIIb signaling promotes lung epithelial proliferation during branching morphogenesis.
Reason: Core function for lung development. FGFR2IIIb-mediated epithelial proliferation is essential for lung morphogenesis.
|
|
GO:0060512
prostate gland morphogenesis
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog for prostate development.
Reason: Specific gland development context. More general gland morphogenesis captures this function.
|
|
GO:0060523
prostate epithelial cord elongation
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog for prostate development.
Reason: Specific prostate developmental context. More general epithelial morphogenesis and gland development terms capture this function.
|
|
GO:0060527
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog for highly specific prostate morphogenesis.
Reason: Overly specific developmental term. General gland morphogenesis captures FGFR2 role without this level of specificity.
|
|
GO:0060529
squamous basal epithelial stem cell differentiation involved in prostate gland acinus development
|
ISS
GO_REF:0000024 |
MARK AS OVER ANNOTATED |
Summary: ISS annotation from mouse ortholog for very specific prostate stem cell context.
Reason: Extremely specific term that goes beyond core FGFR2 function. This level of specificity is not a primary FGFR2 function.
|
|
GO:0060601
lateral sprouting from an epithelium
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. Epithelial sprouting is part of branching morphogenesis that FGFR2 mediates.
Reason: Consistent with FGFR2 role in branching morphogenesis. Lateral sprouting is a core mechanism of epithelial branching in lungs and glands.
|
|
GO:0060615
mammary gland bud formation
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog. Mammary gland develops through FGFR2-dependent mechanisms similar to other glands.
Reason: Example of gland morphogenesis. General gland development terms capture this function.
|
|
GO:0060664
epithelial cell proliferation involved in salivary gland morphogenesis
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGF10/FGFR2IIIb signaling promotes epithelial proliferation in salivary gland development.
Reason: Core function for salivary gland development which is a well-documented FGFR2 function through epithelial-mesenchymal interactions.
|
|
GO:0060667
branch elongation involved in salivary gland morphogenesis
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. Branch elongation is a key aspect of salivary gland branching morphogenesis.
Reason: Core salivary gland development function. Consistent with FGFR2 role in branching morphogenesis.
|
|
GO:0060670
branching involved in labyrinthine layer morphogenesis
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog for placental labyrinthine layer.
Reason: Placental development context. UniProt notes trophoblast function but this specific aspect is not emphasized.
|
|
GO:0060688
regulation of morphogenesis of a branching structure
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2 is a key regulator of branching morphogenesis in multiple organs.
Reason: Core developmental function. FGFR2 regulates branching morphogenesis in lungs, glands, and other organs through epithelial-mesenchymal signaling.
|
|
GO:0060915
mesenchymal cell differentiation involved in lung development
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2IIIc in lung mesenchyme responds to epithelial signals to regulate mesenchymal differentiation.
Reason: Core lung development function. Both epithelial (IIIb) and mesenchymal (IIIc) FGFR2 isoforms contribute to lung development.
|
|
GO:0060916
mesenchymal cell proliferation involved in lung development
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2IIIc in lung mesenchyme promotes proliferation in response to epithelial FGFs.
Reason: Core lung development function for FGFR2IIIc isoform.
|
|
GO:0070372
regulation of ERK1 and ERK2 cascade
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2 activates ERK1/2 (MAPK3/MAPK1) through the RAS-MAPK pathway.
Reason: Core signaling function. ERK1/2 cascade activation is a primary downstream effect of FGFR2 signaling through FRS2/GRB2/SOS/RAS pathway.
|
|
GO:0070374
positive regulation of ERK1 and ERK2 cascade
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from mouse ortholog. FGFR2 positively regulates ERK1/2 cascade activation.
Reason: Core signaling function. More specific child term of MAPK cascade regulation that is well-documented for FGFR2.
|
|
GO:0090263
positive regulation of canonical Wnt signaling pathway
|
ISS
GO_REF:0000024 |
KEEP AS NON CORE |
Summary: ISS annotation from mouse ortholog. Cross-talk between FGF and Wnt pathways occurs during development.
Reason: Indirect pathway cross-talk rather than a direct core function of FGFR2. More specific than general Wnt regulation annotation already reviewed.
|
|
GO:0016020
membrane
|
NAS
PMID:8676562 [Nucleotide sequences at intron 6 and exon 7 junction of fib... |
ACCEPT |
Summary: NAS annotation for membrane localization. FGFR2 is a transmembrane receptor.
Reason: Correct but general term. More specific plasma membrane annotations exist.
Supporting Evidence:
PMID:8676562
Apert syndrome, acrocephalosyndactyly Type I, is an autosomal dominant craniosynostosis comprising acrocephaly, facial dysmorphism and severe syndactyly of the hands and feet.
|
|
GO:0005634
nucleus
|
IDA
PMID:17471512 Translocation of fibroblast growth factor-10 and its recepto... |
KEEP AS NON CORE |
Summary: PMID:17471512 demonstrated nuclear localization of FGF-10 receptor (FGFR2IIIb) in urothelial cells along with its ligand FGF-10.
Reason: Nuclear localization represents a specialized signaling mechanism rather than the primary localization. Main FGFR2 function is at plasma membrane.
Supporting Evidence:
PMID:17471512
The FGF-10 receptor was observed in cell nuclei regardless of the presence or concentration of exogenous rFGF-10 ligand
|
|
GO:0005737
cytoplasm
|
IDA
PMID:17471512 Translocation of fibroblast growth factor-10 and its recepto... |
ACCEPT |
Summary: PMID:17471512 showed FGF-10 receptor (FGFR2IIIb) localizes to cytoplasm in urothelial cells during trafficking.
Reason: FGFR2 is found in cytoplasm during biosynthesis, trafficking, and after internalization.
Supporting Evidence:
PMID:17471512
rFGF-10(no NLS) was found in cytoplasm to a far greater degree than rFGF-10
|
|
GO:0005938
cell cortex
|
IDA
PMID:17471512 Translocation of fibroblast growth factor-10 and its recepto... |
KEEP AS NON CORE |
Summary: PMID:17471512 may have observed FGFR2 at the cell cortex during trafficking or at the plasma membrane interface.
Reason: Cell cortex localization is not a primary FGFR2 localization. May represent trafficking intermediate or plasma membrane-associated pool.
Supporting Evidence:
PMID:17471512
Translocation of fibroblast growth factor-10 and its receptor into nuclei of human urothelial cells.
|
|
GO:0008284
positive regulation of cell population proliferation
|
IGI
PMID:8663044 Receptor specificity of the fibroblast growth factor family. |
ACCEPT |
Summary: IGI (Inferred from Genetic Interaction) annotation from PMID:8663044 which tested multiple FGF-FGFR combinations for mitogenic activity.
Reason: Consistent with core mitogenic function. PMID:8663044 demonstrated proliferative activity of FGFR2 with various FGF ligands.
Supporting Evidence:
PMID:8663044
Receptor specificity of the fibroblast growth factor family.
|
|
GO:0008543
fibroblast growth factor receptor signaling pathway
|
IGI
PMID:8663044 Receptor specificity of the fibroblast growth factor family. |
ACCEPT |
Summary: IGI annotation from PMID:8663044 demonstrating FGF receptor signaling through FGFR2.
Reason: Core biological process. PMID:8663044 is foundational study for FGFR signaling specificity.
Supporting Evidence:
PMID:8663044
Receptor specificity of the fibroblast growth factor family.
|
|
GO:0005007
fibroblast growth factor receptor activity
|
IGI
PMID:10830168 Crystal structures of two FGF-FGFR complexes reveal the dete... |
ACCEPT |
Summary: IGI annotation from PMID:10830168 which determined crystal structures of FGF-FGFR complexes and characterized ligand-receptor specificity.
Reason: Core molecular function. PMID:10830168 provided structural basis for FGF receptor specificity through alternative splicing.
Supporting Evidence:
PMID:10830168
Specificity is achieved through interactions between the N-terminal and central regions of FGFs and two loop regions in D3 that are subject to alternative splicing
|
|
GO:0008543
fibroblast growth factor receptor signaling pathway
|
IPI
PMID:10830168 Crystal structures of two FGF-FGFR complexes reveal the dete... |
ACCEPT |
Summary: IPI annotation from PMID:10830168 based on physical interaction studies of FGF-FGFR complexes.
Reason: Core signaling pathway. Crystal structures revealed basis for ligand binding and receptor activation.
Supporting Evidence:
PMID:10830168
Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity.
|
|
GO:0017134
fibroblast growth factor binding
|
IPI
PMID:8386828 Activation of fibroblast growth factor (FGF) receptors by re... |
ACCEPT |
Summary: IPI annotation from PMID:8386828 demonstrating FGF-5 binding to FGFR2. Competition binding studies showed KD of 0.5-1.5 nM.
Reason: Core molecular function. Direct binding assays demonstrated FGF binding to FGFR2 with high affinity.
Supporting Evidence:
PMID:8386828
the KD for FGF-5-FGFR-1 and FGF-5-FGFR-2 interactions are both between 0.5 and 1.5 x 10(-9) M
|
|
GO:0005007
fibroblast growth factor receptor activity
|
NAS
PMID:8676562 [Nucleotide sequences at intron 6 and exon 7 junction of fib... |
ACCEPT |
Summary: NAS annotation for FGF receptor activity. Duplicate annotation with different evidence code.
Reason: Core molecular function supported by multiple evidence types.
Supporting Evidence:
PMID:8676562
Apert syndrome, acrocephalosyndactyly Type I, is an autosomal dominant craniosynostosis comprising acrocephaly, facial dysmorphism and severe syndactyly of the hands and feet.
|
|
GO:0004713
protein tyrosine kinase activity
|
NAS
PMID:1697263 Cloning and expression of two distinct high-affinity recepto... |
ACCEPT |
Summary: NAS annotation for protein tyrosine kinase activity. FGFR2 is a receptor tyrosine kinase.
Reason: Core molecular function. FGFR2 is a well-characterized receptor tyrosine kinase (EC 2.7.10.1).
Supporting Evidence:
PMID:1697263
Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors.
|
|
GO:0005007
fibroblast growth factor receptor activity
|
NAS
PMID:1400433 A novel form of fibroblast growth factor receptor 2. Alterna... |
ACCEPT |
Summary: NAS annotation from PMID:1400433 which identified alternative splicing creating isoforms with different ligand specificities.
Reason: Core molecular function. PMID:1400433 was important for understanding isoform-specific FGF binding.
Supporting Evidence:
PMID:1400433
A novel form of fibroblast growth factor receptor 2.
|
|
GO:0005007
fibroblast growth factor receptor activity
|
NAS
PMID:1697263 Cloning and expression of two distinct high-affinity recepto... |
ACCEPT |
Summary: NAS annotation for FGF receptor activity. Duplicate with different reference.
Reason: Core molecular function.
Supporting Evidence:
PMID:1697263
Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors.
|
|
GO:0016020
membrane
|
NAS
PMID:1697263 Cloning and expression of two distinct high-affinity recepto... |
ACCEPT |
Summary: NAS annotation for membrane localization. FGFR2 is a single-pass type I membrane protein.
Reason: Correct but general term. More specific plasma membrane annotations exist.
Supporting Evidence:
PMID:1697263
Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors.
|
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-03-06T03:10:37.229091'
end_time: '2026-03-06T03:26:16.731636'
duration_seconds: 939.5
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: FGFR2
gene_symbol: FGFR2
uniprot_accession: P21802
protein_description: 'RecName: Full=Fibroblast growth factor receptor 2; Short=FGFR-2;
EC=2.7.10.1 {ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:18056630, ECO:0000269|PubMed:19410646,
ECO:0000269|PubMed:21454610}; AltName: Full=K-sam; Short=KGFR; AltName: Full=Keratinocyte
growth factor receptor; AltName: CD_antigen=CD332; Flags: Precursor;'
gene_info: Name=FGFR2; Synonyms=BEK, KGFR, KSAM;
organism_full: Homo sapiens (Human).
protein_family: Belongs to the protein kinase superfamily. Tyr protein
protein_domains: FGF_rcpt_fam. (IPR016248); Ig-like_dom. (IPR007110); Ig-like_dom_sf.
(IPR036179); Ig-like_fold. (IPR013783); Ig_I-set. (IPR013098)
provider_config:
timeout: 600
max_retries: 3
parameters:
allowed_domains: []
temperature: 0.1
citation_count: 33
BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.
DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'FGFR2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information
Please provide a comprehensive research report on the gene FGFR2 (gene ID: FGFR2, UniProt: P21802) in human.
The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.
BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.
DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'FGFR2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information
Please provide a comprehensive research report on the gene FGFR2 (gene ID: FGFR2, UniProt: P21802) in human.
The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The requested target FGFR2 matches UniProt P21802 from Homo sapiens and is consistently described in authoritative literature as a single-pass transmembrane receptor tyrosine kinase with three extracellular immunoglobulin-like domains, a transmembrane helix, and an intracellular split tyrosine kinase domain. This aligns with UniProt’s “Fibroblast growth factor receptor 2 (FGFR-2; KGFR/K-sam/CD332)” and the kinase family/domain architecture expected for an RTK. (lau2024clinicaldevelopmentsand pages 2-4, guttieri2023emtautophagycrosstalkrole pages 10-15)
FGFR2 is a member of the FGFR receptor tyrosine kinase family that transduces extracellular fibroblast growth factor (FGF) signals into intracellular phosphorylation-dependent signaling programs that control proliferation, survival, differentiation, and migration. Canonical activation is ligand-dependent dimerization followed by autophosphorylation of tyrosines in the intracellular region, which creates docking sites for adaptor/effector proteins. (lau2024clinicaldevelopmentsand pages 2-4, zhang2024targetingfgfrfor pages 1-3)
FGFR2 is a plasma-membrane receptor with:
- Extracellular region containing three Ig-like domains (D1–D3) (ligand-binding largely mediated by D2/D3),
- Single transmembrane helix,
- Cytoplasmic tyrosine kinase domain (split TK1/TK2) plus C-terminal tail that becomes phosphorylated to recruit signaling proteins. (lau2024clinicaldevelopmentsand pages 2-4, guttieri2023emtautophagycrosstalkrole pages 10-15)
A central concept for FGFR2 functional annotation is alternative splicing of the ligand-binding region (commonly described for FGFR1–3 as exon 8/9 usage) producing IIIb and IIIc isoforms with different tissue expression and ligand specificity:
- FGFR2-IIIb: predominantly epithelial; binds FGF7 (KGF) and FGF10 (among others) and is often referred to as the keratinocyte growth factor receptor (KGFR). (guttieri2023emtautophagycrosstalkrole pages 10-15)
- FGFR2-IIIc: predominantly mesenchymal; binds ligands such as FGF2. (guttieri2023emtautophagycrosstalkrole pages 10-15)
Ligand binding is typically stabilized by heparan sulfate proteoglycans (HSPGs) (paracrine FGFs), while endocrine FGFs require Klotho co-receptors (family-level principle relevant to FGFR2). (lau2024clinicaldevelopmentsand pages 2-4)
Upon FGF engagement (with HSPG support), FGFR2 dimerizes, juxtaposing kinase domains and enabling intermolecular transphosphorylation (autophosphorylation). Review synthesis highlights multiple phosphorylated tyrosines (example residues listed in FGFR2 signaling summaries include Y653/Y654 as key activation loop regulators and additional phosphotyrosines that recruit adaptor proteins). (lau2024clinicaldevelopmentsand pages 2-4)
Two experimentally supported “first-layer” signaling nodes emphasized in mechanistic summaries include:
- FRS2α (FGF receptor substrate 2) as a major docking/scaffold protein; it recruits Grb2/SOS to activate RAS–MAPK and can recruit Gab1 to activate PI3K–AKT. (lau2024clinicaldevelopmentsand pages 2-4, guttieri2023emtautophagycrosstalkrole pages 10-15)
- PLCγ docking/activation (with a site noted for FGFR2b Y769 involvement in PLCγ binding), producing DAG/PKC signaling outputs. (guttieri2023emtautophagycrosstalkrole pages 10-15)
Downstream pathways repeatedly highlighted across 2023–2024 sources include:
- RAS–RAF–MEK–ERK (MAPK),
- PI3K–AKT,
- PLCγ → DAG/PKC,
- JAK/STAT (and additional stress/kinase branches such as p38/JNK in some contexts). (lau2024clinicaldevelopmentsand pages 2-4, guttieri2023emtautophagycrosstalkrole pages 10-15, zhang2024targetingfgfrfor pages 1-3)
FGFR2’s primary biochemical activity is protein tyrosine kinase activity, catalyzing transfer of the γ-phosphate of ATP to tyrosine residues on substrate proteins (including the receptor itself via autophosphorylation), thereby generating phosphotyrosine docking sites that propagate signaling. This is supported by the repeated classification of FGFR2 as a receptor tyrosine kinase whose activation involves kinase-domain autophosphorylation and phosphorylation-dependent recruitment of FRS2/PLCγ and downstream pathways. (lau2024clinicaldevelopmentsand pages 2-4, guttieri2023emtautophagycrosstalkrole pages 10-15, zhang2024targetingfgfrfor pages 1-3)
A 2023 focused analysis emphasizes aberrant expression of the mesenchymal FGFR2c isoform as a mechanism that can promote autocrine signaling and phenotypes such as EMT (epithelial–mesenchymal transition), underscoring the importance of isoform-specific annotation (FGFR2b vs FGFR2c) rather than treating FGFR2 as a single uniform receptor in all tissues. (guttieri2023emtautophagycrosstalkrole pages 10-15)
Two 2024 primary studies substantially refine the field’s understanding of resistance in FGFR2 fusion-positive cholangiocarcinoma:
1) Convergent MAPK pathway alterations as off-target resistance (MD Anderson; Journal of Hepatology, 2024): in 17 patients with repeat sequencing after FGFR inhibitor therapy, 11/17 (64.7%) acquired new FGFR2 mutations and 9/17 (52.9%) acquired MAPK pathway alterations, with many patients showing both categories. This supports a model in which tumors escape FGFR2 dependency through either on-target kinase alterations or reactivation of MAPK signaling. (diperi2024convergentmapkpathway pages 1-3)
2) Prospective molecular resistance profiling (UNLOCK; Clinical Cancer Research, 2024): in cholangiocarcinoma, polyclonal FGFR2 kinase-domain mutations were frequent at resistance (reported as 14/27 iCCA cases), and after irreversible inhibition (futibatinib), resistance mutations narrowed primarily to molecular brake N550 and gatekeeper V565 hotspots. Off-target PI3K/mTOR or MAPK alterations also occurred, sometimes co-existing with on-target mutations. (facchinetti2024understandingandovercoming pages 1-2)
A 2024 PNAS study reports the discovery of lirafugratinib (RLY-4008) as a highly FGFR2-selective irreversible inhibitor, designed by exploiting differential P-loop dynamics between FGFR1 and FGFR2 and covalently engaging an FGFR2 cysteine (Cys491 as described in the study). The work provides quantitative selectivity metrics (e.g., Caliper IC50s FGFR2 0.003 μM vs FGFR1 0.77 μM and FGFR4 15 μM) and emphasizes the translational rationale: sparing FGFR1/FGFR4 may reduce class-limiting toxicities (hyperphosphatemia and diarrhea). (schonherr2024discoveryoflirafugratinib pages 7-9, schonherr2024discoveryoflirafugratinib pages 1-2)
A visual table summarizing potency/selectivity from this work was retrieved (schonherr2024discoveryoflirafugratinib media 3bde7918).
FGFR2 is a clinically actionable target in biomarker-defined subsets of cancer, notably:
- Intrahepatic cholangiocarcinoma (iCCA) where FGFR2 fusions occur in ~10–15% of cases (enabling selection for FGFR inhibitors). (facchinetti2024understandingandovercoming pages 1-2, gonzalezmedina2024clinicalvalueof pages 1-2)
- Gastric cancer where FGFR2 dysregulation frequently occurs via amplification (reported 4–7% overall in one review; other summaries mention broader ranges), and fusions occur less commonly (0.5–3%). (lau2024clinicaldevelopmentsand pages 2-4)
Clinical practice and late-stage development include:
- ATP-competitive FGFR inhibitors (e.g., pemigatinib) used in multiple FGFR-altered solid tumors; efficacy varies by alteration class (fusions tend to respond better than some mutation classes). (rodon2024pemigatinibinpreviously pages 1-2)
- Irreversible inhibitors (e.g., futibatinib), designed to retain activity against some resistance mutations via covalent engagement. (balasooriya2024theirreversiblefgfr pages 5-6)
- FGFR2-selective covalent inhibitors (lirafugratinib/RLY-4008) aiming to improve therapeutic index by avoiding FGFR1/FGFR4 toxicities and expanding coverage of FGFR2 resistance mutations. (schonherr2024discoveryoflirafugratinib pages 7-9, schonherr2024discoveryoflirafugratinib pages 1-2)
A 2024 Clinical Cancer Research study evaluated a hybrid-capture panel in 18 tissue-confirmed FGFR2-fusion iCCA patients and demonstrated:
- Baseline plasma fusion detection: 16/18 (88.9%) plasma-positive for FGFR2 fusion. (gonzalezmedina2024clinicalvalueof pages 1-2, gonzalezmedina2024clinicalvalueof pages 5-7)
- Clinical utility: longitudinal rises in ctDNA or emergence of resistance mutations enabled earlier detection of progression than standard imaging in reported cases. (gonzalezmedina2024clinicalvalueof pages 1-2)
- Lead time: appearance of FGFR2 resistance mutations and increased tumor fraction were detected months before clinical/radiologic progression in example cases, with median lead times reported around ~4.9–7 months in described patients, and an illustrative case with signal 8.4 months before imaging progression. (gonzalezmedina2024clinicalvalueof pages 10-11)
Across 2024 clinical and translational sources, a consistent expert view is that FGFR2 fusions are strong oncogenic drivers and can confer dependency on FGFR signaling (hence sensitivity to FGFR inhibition), but clinical benefit is limited by:
- On-target kinase-domain mutations (including gatekeeper and molecular-brake mutations) that reduce inhibitor binding or increase ATP affinity, and
- Off-target bypass mechanisms, particularly MAPK pathway reactivation and sometimes PI3K/mTOR changes. (diperi2024convergentmapkpathway pages 1-3, facchinetti2024understandingandovercoming pages 1-2)
The 2024 resistance literature supports a strategy of molecularly guided sequencing (switching inhibitor class based on resistance mechanism) and rational combinations (e.g., FGFR inhibitor + MEK inhibitor) for tumors that escape through MAPK pathway changes, though not all bypass alterations are equally suppressible (e.g., KRAS-driven resistance can be difficult to overcome). (diperi2024convergentmapkpathway pages 1-3, facchinetti2024understandingandovercoming pages 1-2)
The development of FGFR2-selective inhibitors is motivated by the expert interpretation that pan-FGFR inhibition produces dose-limiting toxicities partly mediated by FGFR1/FGFR4, constraining efficacy. The PNAS 2024 lirafugratinib study explicitly frames selectivity as a route to maintain efficacy while reducing hyperphosphatemia/diarrhea and improving dosing headroom. (schonherr2024discoveryoflirafugratinib pages 1-2)
| Category | Metric / Finding | Quantitative Value | Source |
|---|---|---|---|
| Prevalence (iCCA) | FGFR2 fusions in Intrahepatic Cholangiocarcinoma | 10–15% (fusions); ~12% (fusions/truncations) | Facchinetti 2024 (facchinetti2024understandingandovercoming pages 1-2); Balasooriya 2024 (balasooriya2024theirreversiblefgfr pages 4-5) |
| Prevalence (Gastric) | FGFR2 Amplifications / Fusions | 4–7% (Amplification); 0.5–3% (Fusions) | Lau 2024 (lau2024clinicaldevelopmentsand pages 2-4); Shan 2024 (shan2024moleculartargetingof pages 4-5) |
| Efficacy (Pemigatinib) | FIGHT-207 Basket Trial (Solid Tumors) | Cohort A (Fusions): ORR 26.5%, mPFS 4.5 mo, mOS 17.5 mo Cohort B (Mutations): ORR 9.4%, mPFS 3.7 mo |
Rodón 2024 (rodon2024pemigatinibinpreviously pages 1-2) |
| Efficacy (Futibatinib) | FGFR2-fusion iCCA (Pivotal Study) | ORR 42% | Cited in DiPeri 2024 (diperi2024convergentmapkpathway pages 1-3) |
| Efficacy (Lirafugratinib) | FGFR2-selective (RLY-4008) in naive iCCA | ORR 73% (Early clinical data, doses ≥70 mg) | Schönherr 2024 (schonherr2024discoveryoflirafugratinib pages 7-9, schonherr2024discoveryoflirafugratinib pages 1-2) |
| Resistance Mechanisms | Polyclonal FGFR2 KD Mutations | 50% frequency post-reversible inhibitors vs 23% post-futibatinib | Facchinetti 2024 (facchinetti2024understandingandovercoming pages 5-6, facchinetti2024understandingandovercoming pages 1-2) |
| Resistance Mechanisms | Acquired Alterations (DiPeri Cohort) | New FGFR2 mutations: 64.7%; MAPK pathway alterations: 52.9% | DiPeri 2024 (diperi2024convergentmapkpathway pages 1-3) |
| Resistance Hotspots | Dominant On-Target Residues | N550 (Molecular Brake) & V565/V564 (Gatekeeper) | Facchinetti 2024 (facchinetti2024understandingandovercoming pages 5-6); Balasooriya 2024 (balasooriya2024theirreversiblefgfr pages 22-24) |
| Liquid Biopsy | Plasma FGFR2 Fusion Detection Rate | 88.9% (16/18 patients) in iCCA | González-Medina 2024 (gonzalezmedina2024clinicalvalueof pages 1-2, gonzalezmedina2024clinicalvalueof pages 5-7) |
| Liquid Biopsy | Molecular vs Radiologic Progression | ctDNA detected progression median 3–7 months earlier than imaging | González-Medina 2024 (gonzalezmedina2024clinicalvalueof pages 10-11) |
Table: Key statistics extracted from recent literature regarding FGFR2 alteration prevalence, inhibitor efficacy, resistance mechanisms, and liquid biopsy performance.
In the phase 2 FIGHT-207 basket trial (previously treated solid tumors with FGFR1–FGFR3 alterations), the primary endpoint ORR was:
- 26.5% in the fusion/rearrangement cohort (13/49),
- 9.4% in the activating non-kinase domain mutation cohort (3/32).
Median PFS was 4.5 months and 3.7 months, respectively, with common TEAEs including hyperphosphatemia (84%) and stomatitis (53%). (rodon2024pemigatinibinpreviously pages 1-2)
In a 2024 resistance profiling cohort, polyclonal FGFR2 kinase-domain mutations were common after reversible inhibitors (e.g., pemigatinib/erdafitinib), and resistance converged on N550 and V565 as dominant hotspots, especially after futibatinib where these remained the principal on-target residues. (facchinetti2024understandingandovercoming pages 5-6, facchinetti2024understandingandovercoming pages 1-2)
In FGFR2-fusion iCCA, baseline and longitudinal ctDNA/cfDNA features were strongly associated with outcomes:
- Baseline plasma fusion detection: 88.9% (16/18). (gonzalezmedina2024clinicalvalueof pages 1-2, gonzalezmedina2024clinicalvalueof pages 5-7)
- High baseline ctDNA metrics were associated with substantially shorter median PFS and OS in reported stratifications (e.g., PFS 6.53 vs 13.3 months for high vs low baseline ctDNA, P=0.0018; OS 10.6 months vs not reached, P=0.0198). (gonzalezmedina2024clinicalvalueof pages 7-8)
This report focuses on experimentally supported receptor biology and 2024 translational evidence. Some classical FGFR2 developmental biology and older foundational signaling work is not exhaustively reviewed here because the user requested prioritization of 2023–2024 sources; however, the mechanistic framework summarized above is consistent across the modern reviews and primary clinical/translational studies cited.
References
(lau2024clinicaldevelopmentsand pages 2-4): David K. Lau, Jack P. Collin, and John M. Mariadason. Clinical developments and challenges in treating fgfr2-driven gastric cancer. Biomedicines, 12:1117, May 2024. URL: https://doi.org/10.3390/biomedicines12051117, doi:10.3390/biomedicines12051117. This article has 19 citations.
(guttieri2023emtautophagycrosstalkrole pages 10-15): L Guttieri. Emt/autophagy crosstalk: role of the aberrant expression of the mesenchymal fgfr2c isoform. Unknown journal, 2023.
(zhang2024targetingfgfrfor pages 1-3): Pei Zhang, Lin Yue, QingQing Leng, Chen Chang, Cailing Gan, Tinghong Ye, and Dan Cao. Targeting fgfr for cancer therapy. Journal of Hematology & Oncology, Jun 2024. URL: https://doi.org/10.1186/s13045-024-01558-1, doi:10.1186/s13045-024-01558-1. This article has 89 citations and is from a domain leading peer-reviewed journal.
(diperi2024convergentmapkpathway pages 1-3): Timothy P. DiPeri, Ming Zhao, Kurt W. Evans, Kaushik Varadarajan, Tyler Moss, Stephen Scott, Michael P. Kahle, Charnel C. Byrnes, Huiqin Chen, Sunyoung S. Lee, Abdel-Baset Halim, Hiroshi Hirai, Volker Wacheck, Lawrence N. Kwong, Jordi Rodon, Milind Javle, and Funda Meric-Bernstam. Convergent mapk pathway alterations mediate acquired resistance to fgfr inhibitors in fgfr2 fusion-positive cholangiocarcinoma. Journal of Hepatology, 80:322-334, Feb 2024. URL: https://doi.org/10.1016/j.jhep.2023.10.041, doi:10.1016/j.jhep.2023.10.041. This article has 34 citations and is from a highest quality peer-reviewed journal.
(facchinetti2024understandingandovercoming pages 1-2): Francesco Facchinetti, Yohann Loriot, Floriane Brayé, Damien Vasseur, Rastislav Bahleda, Ludovic Bigot, Rémy Barbé, Catline Nobre, David Combarel, Stefan Michiels, Antoine Italiano, Cristina Smolenschi, Lambros Tselikas, Jean-Yves Scoazec, Santiago Ponce-Aix, Benjamin Besse, Fabrice André, Ken A. Olaussen, Antoine Hollebecque, and Luc Friboulet. Understanding and overcoming resistance to selective fgfr inhibitors across fgfr2-driven malignancies. Clinical Cancer Research, 30:4943-4956, Sep 2024. URL: https://doi.org/10.1158/1078-0432.ccr-24-1834, doi:10.1158/1078-0432.ccr-24-1834. This article has 32 citations and is from a highest quality peer-reviewed journal.
(schonherr2024discoveryoflirafugratinib pages 7-9): Heike Schönherr, Pelin Ayaz, Alexander M. Taylor, Jessica B. Casaletto, B. Barry Touré, Demetri T. Moustakas, Brandi M. Hudson, Roberto Valverde, Songping Zhao, Patrick J. O’Hearn, Lindsey Foster, Dina A. Sharon, Sam Garfinkle, Fabrizio Giordanetto, André Lescarbeau, Ravi Kurukulasuriya, Nastaran Gerami-Moayed, Dejan Maglic, Kamil Bruderek, Gaauri Naik, Hakan Gunaydin, Mary M. Mader, Alessandro A. Boezio, Thomas H. McLean, Rongfeng Chen, Yanxia Wang, David E. Shaw, James Watters, and Donald A. Bergstrom. Discovery of lirafugratinib (rly-4008), a highly selective irreversible small-molecule inhibitor of fgfr2. Proceedings of the National Academy of Sciences of the United States of America, Feb 2024. URL: https://doi.org/10.1073/pnas.2317756121, doi:10.1073/pnas.2317756121. This article has 57 citations and is from a highest quality peer-reviewed journal.
(schonherr2024discoveryoflirafugratinib pages 1-2): Heike Schönherr, Pelin Ayaz, Alexander M. Taylor, Jessica B. Casaletto, B. Barry Touré, Demetri T. Moustakas, Brandi M. Hudson, Roberto Valverde, Songping Zhao, Patrick J. O’Hearn, Lindsey Foster, Dina A. Sharon, Sam Garfinkle, Fabrizio Giordanetto, André Lescarbeau, Ravi Kurukulasuriya, Nastaran Gerami-Moayed, Dejan Maglic, Kamil Bruderek, Gaauri Naik, Hakan Gunaydin, Mary M. Mader, Alessandro A. Boezio, Thomas H. McLean, Rongfeng Chen, Yanxia Wang, David E. Shaw, James Watters, and Donald A. Bergstrom. Discovery of lirafugratinib (rly-4008), a highly selective irreversible small-molecule inhibitor of fgfr2. Proceedings of the National Academy of Sciences of the United States of America, Feb 2024. URL: https://doi.org/10.1073/pnas.2317756121, doi:10.1073/pnas.2317756121. This article has 57 citations and is from a highest quality peer-reviewed journal.
(schonherr2024discoveryoflirafugratinib media 3bde7918): Heike Schönherr, Pelin Ayaz, Alexander M. Taylor, Jessica B. Casaletto, B. Barry Touré, Demetri T. Moustakas, Brandi M. Hudson, Roberto Valverde, Songping Zhao, Patrick J. O’Hearn, Lindsey Foster, Dina A. Sharon, Sam Garfinkle, Fabrizio Giordanetto, André Lescarbeau, Ravi Kurukulasuriya, Nastaran Gerami-Moayed, Dejan Maglic, Kamil Bruderek, Gaauri Naik, Hakan Gunaydin, Mary M. Mader, Alessandro A. Boezio, Thomas H. McLean, Rongfeng Chen, Yanxia Wang, David E. Shaw, James Watters, and Donald A. Bergstrom. Discovery of lirafugratinib (rly-4008), a highly selective irreversible small-molecule inhibitor of fgfr2. Proceedings of the National Academy of Sciences of the United States of America, Feb 2024. URL: https://doi.org/10.1073/pnas.2317756121, doi:10.1073/pnas.2317756121. This article has 57 citations and is from a highest quality peer-reviewed journal.
(gonzalezmedina2024clinicalvalueof pages 1-2): Alberto González-Medina, Maria Vila-Casadesús, Marina Gomez-Rey, Carles Fabregat-Franco, Alexandre Sierra, Tian V. Tian, Florian Castet, Gloria Castillo, Judit Matito, Paola Martinez, Josep M. Miquel, Paolo Nuciforo, Raquel Pérez-López, Teresa Macarulla, and Ana Vivancos. Clinical value of liquid biopsy in patients with fgfr2 fusion–positive cholangiocarcinoma during targeted therapy. Clinical Cancer Research, 30:4491-4504, Jul 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-3780, doi:10.1158/1078-0432.ccr-23-3780. This article has 21 citations and is from a highest quality peer-reviewed journal.
(rodon2024pemigatinibinpreviously pages 1-2): Jordi Rodón, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, and Lipika Goyal. Pemigatinib in previously treated solid tumors with activating fgfr1–fgfr3 alterations: phase 2 fight-207 basket trial. Nature Medicine, 30:1645-1654, May 2024. URL: https://doi.org/10.1038/s41591-024-02934-7, doi:10.1038/s41591-024-02934-7. This article has 61 citations and is from a highest quality peer-reviewed journal.
(balasooriya2024theirreversiblefgfr pages 5-6): Eranga R. Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L. Norden, Ryan B. Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John Tyhonas, Matthew Lardy, Kathryn B. Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa S. Silveira, and Nabeel Bardeesy. The irreversible fgfr inhibitor kin-3248 overcomes fgfr2 kinase domain mutations. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:2181-2192, Mar 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-3588, doi:10.1158/1078-0432.ccr-23-3588. This article has 18 citations.
(gonzalezmedina2024clinicalvalueof pages 5-7): Alberto González-Medina, Maria Vila-Casadesús, Marina Gomez-Rey, Carles Fabregat-Franco, Alexandre Sierra, Tian V. Tian, Florian Castet, Gloria Castillo, Judit Matito, Paola Martinez, Josep M. Miquel, Paolo Nuciforo, Raquel Pérez-López, Teresa Macarulla, and Ana Vivancos. Clinical value of liquid biopsy in patients with fgfr2 fusion–positive cholangiocarcinoma during targeted therapy. Clinical Cancer Research, 30:4491-4504, Jul 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-3780, doi:10.1158/1078-0432.ccr-23-3780. This article has 21 citations and is from a highest quality peer-reviewed journal.
(gonzalezmedina2024clinicalvalueof pages 10-11): Alberto González-Medina, Maria Vila-Casadesús, Marina Gomez-Rey, Carles Fabregat-Franco, Alexandre Sierra, Tian V. Tian, Florian Castet, Gloria Castillo, Judit Matito, Paola Martinez, Josep M. Miquel, Paolo Nuciforo, Raquel Pérez-López, Teresa Macarulla, and Ana Vivancos. Clinical value of liquid biopsy in patients with fgfr2 fusion–positive cholangiocarcinoma during targeted therapy. Clinical Cancer Research, 30:4491-4504, Jul 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-3780, doi:10.1158/1078-0432.ccr-23-3780. This article has 21 citations and is from a highest quality peer-reviewed journal.
(balasooriya2024theirreversiblefgfr pages 4-5): Eranga R. Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L. Norden, Ryan B. Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John Tyhonas, Matthew Lardy, Kathryn B. Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa S. Silveira, and Nabeel Bardeesy. The irreversible fgfr inhibitor kin-3248 overcomes fgfr2 kinase domain mutations. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:2181-2192, Mar 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-3588, doi:10.1158/1078-0432.ccr-23-3588. This article has 18 citations.
(shan2024moleculartargetingof pages 4-5): Khine S. Shan, Shivani Dalal, Nyein Nyein Thaw Dar, Omani McLish, Matthew Salzberg, and Brian A. Pico. Molecular targeting of the fibroblast growth factor receptor pathway across various cancers. International Journal of Molecular Sciences, 25:849, Jan 2024. URL: https://doi.org/10.3390/ijms25020849, doi:10.3390/ijms25020849. This article has 24 citations.
(facchinetti2024understandingandovercoming pages 5-6): Francesco Facchinetti, Yohann Loriot, Floriane Brayé, Damien Vasseur, Rastislav Bahleda, Ludovic Bigot, Rémy Barbé, Catline Nobre, David Combarel, Stefan Michiels, Antoine Italiano, Cristina Smolenschi, Lambros Tselikas, Jean-Yves Scoazec, Santiago Ponce-Aix, Benjamin Besse, Fabrice André, Ken A. Olaussen, Antoine Hollebecque, and Luc Friboulet. Understanding and overcoming resistance to selective fgfr inhibitors across fgfr2-driven malignancies. Clinical Cancer Research, 30:4943-4956, Sep 2024. URL: https://doi.org/10.1158/1078-0432.ccr-24-1834, doi:10.1158/1078-0432.ccr-24-1834. This article has 32 citations and is from a highest quality peer-reviewed journal.
(balasooriya2024theirreversiblefgfr pages 22-24): Eranga R. Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L. Norden, Ryan B. Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John Tyhonas, Matthew Lardy, Kathryn B. Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa S. Silveira, and Nabeel Bardeesy. The irreversible fgfr inhibitor kin-3248 overcomes fgfr2 kinase domain mutations. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:2181-2192, Mar 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-3588, doi:10.1158/1078-0432.ccr-23-3588. This article has 18 citations.
(gonzalezmedina2024clinicalvalueof pages 7-8): Alberto González-Medina, Maria Vila-Casadesús, Marina Gomez-Rey, Carles Fabregat-Franco, Alexandre Sierra, Tian V. Tian, Florian Castet, Gloria Castillo, Judit Matito, Paola Martinez, Josep M. Miquel, Paolo Nuciforo, Raquel Pérez-López, Teresa Macarulla, and Ana Vivancos. Clinical value of liquid biopsy in patients with fgfr2 fusion–positive cholangiocarcinoma during targeted therapy. Clinical Cancer Research, 30:4491-4504, Jul 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-3780, doi:10.1158/1078-0432.ccr-23-3780. This article has 21 citations and is from a highest quality peer-reviewed journal.
FGFR2 encodes a receptor tyrosine kinase with tissue-specific isoform switching that determines ligand specificity.
| Isoform | UniProt ID | Exon Usage | Ligand Specificity | Tissue Expression |
|---|---|---|---|---|
| FGFR2IIIb | P21802-1 | Exon IIIb | FGF1, FGF3, FGF7 (KGF), FGF10 | EPITHELIAL |
| FGFR2IIIc | P21802-3 | Exon IIIc | FGF1, FGF2, FGF4, FGF6, FGF9 | MESENCHYMAL |
The Ig-like domain III is alternatively spliced:
- Exon IIIb encodes epithelial-specific splice variant
- Exon IIIc encodes mesenchymal-specific splice variant
This creates mutually exclusive ligand binding:
- FGF7 (KGF) binds ONLY to IIIb (epithelial)
- FGF2 binds preferentially to IIIc (mesenchymal)
The IIIb/IIIc isoform switching enables paracrine signaling:
- Mesenchyme produces FGF7/10 → signals to epithelium (IIIb)
- Epithelium produces FGF2/4 → signals to mesenchyme (IIIc)
This is critical for:
- Limb development
- Lung branching morphogenesis
- Prostate development
- Wound healing
These may act as decoy receptors, similar to soluble FAS.
Isoform switching in cancer:
- Epithelial-to-mesenchymal transition (EMT) includes IIIb→IIIc switch
- Some cancers inappropriately express IIIc in epithelial contexts
- Mis-splicing correlates with metastatic potential
id: P21802
gene_symbol: FGFR2
product_type: PROTEIN
status: COMPLETE
taxon:
id: NCBITaxon:9606
label: Homo sapiens
description: >-
FGFR2 (Fibroblast Growth Factor Receptor 2) encodes a receptor tyrosine kinase
that mediates FGF signaling in development, tissue repair, and homeostasis.
CRITICAL ISOFORM BIOLOGY: Alternative splicing of exon IIIb vs IIIc in the third
Ig-like domain creates isoforms with MUTUALLY EXCLUSIVE ligand specificities:
(1) FGFR2IIIb (P21802-3, KGFR) is expressed in EPITHELIAL cells and binds FGF1,
FGF3, FGF7 (KGF), and FGF10. FGF7 and FGF10 bind ONLY to IIIb.
(2) FGFR2IIIc (P21802-1, BEK) is expressed in MESENCHYMAL cells and binds FGF1,
FGF2, FGF4, FGF6, and FGF9. FGF2 binds preferentially to IIIc.
This isoform switching enables PARACRINE signaling between epithelium and mesenchyme:
mesenchyme produces FGF7/10 to signal to epithelial IIIb, while epithelium produces
FGF2/4 to signal to mesenchymal IIIc. Critical for limb development, lung branching
morphogenesis, and wound healing.
Additional isoforms: Secreted/soluble forms (P21802-14, P21802-19) may act as
decoy receptors. Numerous other splice variants exist with various domain combinations.
Cancer relevance: IIIb-to-IIIc isoform switching accompanies epithelial-mesenchymal
transition (EMT) and correlates with metastatic potential in some cancers.
alternative_products:
- name: 1 (BEK, FGFR2IIIc)
id: P21802-1
- name: 2 (Short)
id: P21802-2
sequence_note: VSP_002978
- name: 3 (BFR-1, FGFR2IIIb, KGFR)
id: P21802-3
sequence_note: VSP_002969, VSP_002970, VSP_002971,
- name: 4 (K-sam)
id: P21802-4
sequence_note: VSP_002964, VSP_002969, VSP_002970,
- name: 5 (K-sam-I, BEK, IgIIIc)
id: P21802-5
sequence_note: VSP_002975
- name: 6 (K-sam-IIC2)
id: P21802-6
sequence_note: VSP_002975, VSP_002984
- name: 7 (K-sam-IIC3)
id: P21802-8
sequence_note: VSP_002975, VSP_002978
- name: 8 (K-sam-IV, Soluble KGFR)
id: P21802-14
sequence_note: VSP_002965, VSP_002966
- name: 9 (K-sam-III)
id: P21802-15
sequence_note: VSP_002968
- name: 10 (TK14)
id: P21802-16
sequence_note: VSP_002967, VSP_002975
- name: '11'
id: P21802-17
sequence_note: VSP_002969, VSP_002970, VSP_002971,
- name: 12 (K-sam-IIC1, KGFR, IgIIIb)
id: P21802-18
sequence_note: VSP_002969, VSP_002970, VSP_002971,
- name: 13 (Soluble KGFR)
id: P21802-19
sequence_note: VSP_002969, VSP_002970, VSP_002971,
- name: '14'
id: P21802-20
sequence_note: VSP_019608, VSP_019609
- name: '15'
id: P21802-21
sequence_note: VSP_002964, VSP_041915
- name: '16'
id: P21802-22
sequence_note: VSP_002964, VSP_002969, VSP_002970,
- name: '17'
id: P21802-23
sequence_note: VSP_041914
existing_annotations:
- term:
id: GO:0005007
label: fibroblast growth factor receptor activity
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
FGFR2 is unambiguously a fibroblast growth factor receptor. UniProt confirms
it is a "Tyrosine-protein kinase that acts as a cell-surface receptor for
fibroblast growth factors." This applies to all transmembrane isoforms (both
IIIb/KGFR and IIIc/BEK), though with different ligand specificities. Deep
research confirms FGFR2 as a receptor tyrosine kinase whose primary function
is transducing FGF signals via autophosphorylation and downstream pathway
activation.
action: ACCEPT
reason: >-
Core molecular function of FGFR2. Extensive experimental evidence from multiple
studies (PMID:8663044, PMID:16597617, PMID:15629145) demonstrates FGF receptor
activity. The IBA annotation appropriately captures the conserved function.
supported_by:
- reference_id: UniProtKB:P21802
supporting_text: "Tyrosine-protein kinase that acts as a cell-surface receptor
for fibroblast growth factors"
- reference_id: file:human/FGFR2/FGFR2-deep-research-falcon.md
supporting_text: "FGFR2 is a member of the FGFR receptor tyrosine kinase family
that transduces extracellular fibroblast growth factor (FGF) signals into
intracellular phosphorylation-dependent signaling programs that control
proliferation, survival, differentiation, and migration."
- term:
id: GO:0005886
label: plasma membrane
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
Plasma membrane localization is confirmed for all transmembrane FGFR2 isoforms
(IIIb and IIIc). However, secreted isoforms (P21802-14, P21802-19) are not
plasma membrane-localized. The annotation is appropriate at the gene level
since most functional isoforms are transmembrane.
action: ACCEPT
reason: >-
UniProt confirms "Cell membrane; Single-pass type I membrane protein" for
main
isoforms. Extensive localization data supports plasma membrane localization
for functional receptor isoforms.
supported_by:
- reference_id: UniProtKB:P21802
supporting_text: "SUBCELLULAR LOCATION: Cell membrane; Single-pass type
I membrane protein"
- term:
id: GO:0008284
label: positive regulation of cell population proliferation
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
FGFR2 signaling promotes cell proliferation in keratinocytes and immature
osteoblasts. UniProt notes it "Promotes cell proliferation in keratinocytes
and immature osteoblasts." This is a well-established downstream effect of
FGF signaling through both IIIb and IIIc isoforms.
action: ACCEPT
reason: >-
Core biological process for FGFR2. Multiple studies demonstrate proliferative
effects (PMID:8663044, PMID:15629145, PMID:16597617). This applies to both
major splice variants with different ligands driving the same outcome.
supported_by:
- reference_id: UniProtKB:P21802
supporting_text: "Promotes cell proliferation in keratinocytes and immature
osteoblasts"
- term:
id: GO:0008543
label: fibroblast growth factor receptor signaling pathway
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
FGFR2 is a core component of FGF receptor signaling. Ligand binding leads
to
receptor dimerization, autophosphorylation, and activation of downstream
cascades including PLCG1, MAPK, and PI3K/AKT pathways.
action: ACCEPT
reason: >-
Fundamental role of FGFR2. UniProt extensively documents signaling mechanism
including phosphorylation of PLCG1, FRS2, and activation of RAS-MAPK and
AKT pathways. Both IIIb and IIIc isoforms signal through these pathways.
supported_by:
- reference_id: UniProtKB:P21802
supporting_text: "Phosphorylation of FRS2 triggers recruitment of GRB2,
GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1
and the MAP kinase signaling pathway"
- term:
id: GO:0001525
label: angiogenesis
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
FGF signaling through FGFRs is known to promote angiogenesis, particularly
FGF2 signaling through FGFR2IIIc (mesenchymal isoform). However, this may
be more prominent for FGFR1 in endothelial cells. The annotation is reasonable
but likely represents a non-core function.
action: KEEP_AS_NON_CORE
reason: >-
Angiogenesis is documented for FGF/FGFR signaling generally, but FGFR2's
primary roles are in epithelial-mesenchymal signaling for organ development
rather than vascular biology. This is a secondary rather than core function.
- term:
id: GO:0043410
label: positive regulation of MAPK cascade
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
MAPK cascade activation is a core downstream signaling event for FGFR2.
UniProt confirms that FRS2 phosphorylation leads to recruitment of GRB2/SOS1
and activation of RAS-MAPK signaling.
action: ACCEPT
reason: >-
Core signaling output of FGFR2. Well-documented in UniProt and multiple
publications (PMID:15629145, PMID:17623664). Both IIIb and IIIc isoforms
activate MAPK upon ligand binding.
supported_by:
- reference_id: UniProtKB:P21802
supporting_text: "mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and
the MAP kinase signaling pathway"
- term:
id: GO:0043235
label: receptor complex
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
FGFR2 forms homodimers upon ligand binding and also forms complexes with
heparan sulfate proteoglycan co-receptors. UniProt confirms "Homodimer after
ligand binding."
action: ACCEPT
reason: >-
FGFR2 functions as part of a receptor complex including FGF ligands, heparan
sulfate, and in some cases KLB (for FGF19/21). Dimerization is required for
receptor activation.
supported_by:
- reference_id: UniProtKB:P21802
supporting_text: "Monomer. Homodimer after ligand binding."
- term:
id: GO:0017134
label: fibroblast growth factor binding
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
FGFR2 binds multiple FGFs with isoform-specific preferences. IIIc (P21802-1)
has high affinity for FGF1, FGF2; IIIb (P21802-3) has high affinity for FGF1,
FGF7. CRITICAL ISOFORM NOTE - FGF7 binds ONLY to IIIb (epithelial); FGF2 binds
preferentially to IIIc (mesenchymal).
action: ACCEPT
reason: >-
Core molecular function. Extensive structural and biochemical data (PMID:8663044,
PMID:10830168, PMID:12591959) document FGF binding. The annotation at gene
level is appropriate though ligand specificity differs by isoform.
supported_by:
- reference_id: UniProtKB:P21802
supporting_text: "Isoform 1 has high affinity for FGF1 and FGF2, but low
affinity for FGF7. Isoform 3 has high affinity for FGF1 and FGF7"
- term:
id: GO:0000166
label: nucleotide binding
evidence_type: IEA
original_reference_id: GO_REF:0000043
review:
summary: >-
FGFR2 is a tyrosine kinase that binds ATP for its catalytic activity.
Nucleotide binding is accurate but overly general - ATP binding is more specific.
action: ACCEPT
reason: >-
True but general. FGFR2 has a kinase domain that binds ATP. The more specific
term "ATP binding" is also annotated and preferred.
- term:
id: GO:0004672
label: protein kinase activity
evidence_type: IEA
original_reference_id: GO_REF:0000002
review:
summary: >-
FGFR2 is a protein kinase. The annotation is correct but "protein tyrosine
kinase activity" is more specific and preferred.
action: ACCEPT
reason: >-
Correct parent term. FGFR2 has documented kinase activity (EC 2.7.10.1).
More specific child term annotations also exist.
- term:
id: GO:0004713
label: protein tyrosine kinase activity
evidence_type: IEA
original_reference_id: GO_REF:0000120
review:
summary: >-
FGFR2 is a receptor tyrosine kinase that autophosphorylates and phosphorylates
substrates including PLCG1, FRS2, and PAK4 on tyrosine residues.
action: ACCEPT
reason: >-
Core molecular function. UniProt confirms EC 2.7.10.1 classification and
documents phosphorylation of multiple substrates. Applies to all kinase-
containing isoforms.
supported_by:
- reference_id: UniProtKB:P21802
supporting_text: "Phosphorylates PLCG1, FRS2 and PAK4"
- term:
id: GO:0004714
label: transmembrane receptor protein tyrosine kinase activity
evidence_type: IEA
original_reference_id: GO_REF:0000003
review:
summary: >-
FGFR2 is a single-pass type I transmembrane receptor tyrosine kinase. This
is the most specific and appropriate molecular function term for membrane-
bound isoforms.
action: ACCEPT
reason: >-
Most specific appropriate MF term for transmembrane FGFR2 isoforms. Note
that secreted isoforms (P21802-14, P21802-19) lack transmembrane domain
and kinase activity.
- term:
id: GO:0005007
label: fibroblast growth factor receptor activity
evidence_type: IEA
original_reference_id: GO_REF:0000120
review:
summary: >-
Duplicate of IBA annotation. FGFR2 is unambiguously an FGF receptor.
action: ACCEPT
reason: >-
Core function - duplicates IBA annotation with different evidence. Correct.
- term:
id: GO:0005524
label: ATP binding
evidence_type: IEA
original_reference_id: GO_REF:0000120
review:
summary: >-
FGFR2 kinase domain binds ATP. Crystal structures confirm ATP binding
(PDB entries with ATP analogs).
action: ACCEPT
reason: >-
Core function for kinase activity. Structural data confirms ATP binding site.
- term:
id: GO:0005576
label: extracellular region
evidence_type: IEA
original_reference_id: GO_REF:0000044
review:
summary: >-
The secreted/soluble isoforms (P21802-14 soluble KGFR, P21802-19 soluble KGFR)
are found in the extracellular region. For transmembrane isoforms, the
N-terminal region including Ig-like domains is extracellular.
action: ACCEPT
reason: >-
Appropriate for secreted isoforms. UniProt confirms isoforms 8 (K-sam-IV,
Soluble KGFR) and 13 (Soluble KGFR) are secreted forms that would localize
to the extracellular region.
- term:
id: GO:0005794
label: Golgi apparatus
evidence_type: IEA
original_reference_id: GO_REF:0000044
review:
summary: >-
FGFR2 is N-glycosylated and transits through the Golgi. UniProt notes
"N-glycan chains undergo further maturation to an Endo H-resistant form
in the Golgi apparatus."
action: ACCEPT
reason: >-
FGFR2 passes through Golgi during maturation. Also documented as
"Golgi apparatus" in subcellular location. Represents trafficking intermediate.
supported_by:
- reference_id: UniProtKB:P21802
supporting_text: "SUBCELLULAR LOCATION: Cell membrane; Single-pass type
I membrane protein. Golgi apparatus."
- term:
id: GO:0005886
label: plasma membrane
evidence_type: IEA
original_reference_id: GO_REF:0000044
review:
summary: >-
Duplicate of IBA annotation. Plasma membrane localization for transmembrane
isoforms is well established.
action: ACCEPT
reason: >-
Correct - duplicates IBA with different evidence.
- term:
id: GO:0006915
label: apoptotic process
evidence_type: IEA
original_reference_id: GO_REF:0000043
review:
summary: >-
FGFR2 has complex effects on apoptosis - it can promote apoptosis in
differentiated osteoblasts but inhibit it in keratinocytes and immature
osteoblasts. The UniProt keyword may be too general.
action: KEEP_AS_NON_CORE
reason: >-
UniProt notes FGFR2 "promotes apoptosis in differentiated osteoblasts" but
this is context-dependent and not a primary function. The annotation is
valid but represents a secondary/context-specific role.
supported_by:
- reference_id: UniProtKB:P21802
supporting_text: "Promotes cell proliferation in keratinocytes and immature
osteoblasts, but promotes apoptosis in differentiated osteoblasts"
- term:
id: GO:0008201
label: heparin binding
evidence_type: IEA
original_reference_id: GO_REF:0000043
review:
summary: >-
FGFR2 binds heparan sulfate glycosaminoglycans which serve as coreceptors.
Heparin (a highly sulfated heparan sulfate) is used experimentally.
action: ACCEPT
reason: >-
Documented function. UniProt confirms "Affinity for fibroblast growth factors
(FGFs) is increased by heparan sulfate glycosaminoglycans that function as
coreceptors." Crystal structures show heparin binding (PMID:11069186).
supported_by:
- reference_id: UniProtKB:P21802
supporting_text: "Affinity for fibroblast growth factors (FGFs) is increased
by heparan sulfate glycosaminoglycans that function as coreceptors"
- term:
id: GO:0008284
label: positive regulation of cell population proliferation
evidence_type: IEA
original_reference_id: GO_REF:0000120
review:
summary: >-
Duplicate of IBA annotation. FGFR2 promotes cell proliferation.
action: ACCEPT
reason: >-
Correct - duplicates IBA with different evidence.
- term:
id: GO:0008543
label: fibroblast growth factor receptor signaling pathway
evidence_type: IEA
original_reference_id: GO_REF:0000120
review:
summary: >-
Duplicate of IBA annotation. FGFR2 is a core component of FGF signaling.
action: ACCEPT
reason: >-
Correct - duplicates IBA with different evidence.
- term:
id: GO:0016020
label: membrane
evidence_type: IEA
original_reference_id: GO_REF:0000002
review:
summary: >-
Transmembrane FGFR2 isoforms are integral membrane proteins. This is a
parent term of plasma membrane - overly general but not wrong.
action: ACCEPT
reason: >-
Correct but general. More specific annotations (plasma membrane) exist.
- term:
id: GO:0016301
label: kinase activity
evidence_type: IEA
original_reference_id: GO_REF:0000043
review:
summary: >-
FGFR2 has kinase activity. This is a parent of the more specific protein
tyrosine kinase activity annotations.
action: ACCEPT
reason: >-
Correct but overly general. More specific annotations exist.
- term:
id: GO:0016740
label: transferase activity
evidence_type: IEA
original_reference_id: GO_REF:0000043
review:
summary: >-
Kinases are transferases (transfer phosphate groups). This is very general
but technically correct.
action: ACCEPT
reason: >-
Correct parent term. Very general but valid.
- term:
id: GO:0031410
label: cytoplasmic vesicle
evidence_type: IEA
original_reference_id: GO_REF:0000120
review:
summary: >-
FGFR2 is found in cytoplasmic vesicles during internalization after ligand
binding. UniProt notes "After ligand binding, the activated receptor is
rapidly internalized and degraded."
action: ACCEPT
reason: >-
Valid location during receptor trafficking/internalization.
supported_by:
- reference_id: UniProtKB:P21802
supporting_text: "After ligand binding, the activated receptor is rapidly
internalized and degraded"
- term:
id: GO:0033688
label: regulation of osteoblast proliferation
evidence_type: IEA
original_reference_id: GO_REF:0000117
review:
summary: >-
FGFR2 regulates osteoblast proliferation - it promotes proliferation in
immature osteoblasts. This is relevant to craniosynostosis syndromes caused
by FGFR2 mutations.
action: ACCEPT
reason: >-
UniProt confirms FGFR2 "Promotes cell proliferation in keratinocytes and
immature osteoblasts" and "Plays an essential role in the regulation of
osteoblast differentiation, proliferation and apoptosis."
- term:
id: GO:0043009
label: chordate embryonic development
evidence_type: IEA
original_reference_id: GO_REF:0000117
review:
summary: >-
FGFR2 is required for normal embryonic development. UniProt confirms it is
"Required for normal embryonic patterning, trophoblast function, limb bud
development, lung morphogenesis, osteogenesis and skin development."
action: KEEP_AS_NON_CORE
reason: >-
Valid but very general developmental term. More specific developmental
processes (limb, lung, skeleton) are better descriptors of FGFR2 function.
- term:
id: GO:0043410
label: positive regulation of MAPK cascade
evidence_type: IEA
original_reference_id: GO_REF:0000117
review:
summary: >-
Duplicate annotation (IBA already reviewed). MAPK cascade activation is a
core downstream signaling output of FGFR2.
action: ACCEPT
reason: >-
Duplicates IBA with different evidence. Core signaling function.
- term:
id: GO:0045595
label: regulation of cell differentiation
evidence_type: IEA
original_reference_id: GO_REF:0000117
review:
summary: >-
FGFR2 regulates differentiation of multiple cell types including osteoblasts,
keratinocytes, and epithelial cells. This is a core function.
action: ACCEPT
reason: >-
UniProt confirms role in "regulation of cell proliferation, differentiation,
migration and apoptosis." Applies to both IIIb (epithelial differentiation)
and IIIc (mesenchymal differentiation) isoforms.
- term:
id: GO:0048562
label: embryonic organ morphogenesis
evidence_type: IEA
original_reference_id: GO_REF:0000117
review:
summary: >-
FGFR2 is required for morphogenesis of multiple embryonic organs including
limbs, lungs, and craniofacial structures. UniProt confirms it is "Required
for normal embryonic patterning, trophoblast function, limb bud development,
lung morphogenesis, osteogenesis and skin development."
action: ACCEPT
reason: >-
Core developmental function. FGFR2 is essential for morphogenesis of
multiple organs through epithelial-mesenchymal interactions. Consistent
with ISS annotation for the same term.
supported_by:
- reference_id: UniProtKB:P21802
supporting_text: "Required for normal embryonic patterning, trophoblast
function, limb bud development, lung morphogenesis, osteogenesis and
skin development"
- term:
id: GO:0048705
label: skeletal system morphogenesis
evidence_type: IEA
original_reference_id: GO_REF:0000117
review:
summary: >-
FGFR2 is critical for skeletal development. Mutations cause multiple
craniosynostosis syndromes (Crouzon, Apert, Pfeiffer, Jackson-Weiss).
action: ACCEPT
reason: >-
UniProt confirms "required for normal skeleton development" and documents
multiple skeletal disorder phenotypes from FGFR2 mutations.
- term:
id: GO:1904888
label: cranial skeletal system development
evidence_type: IEA
original_reference_id: GO_REF:0000117
review:
summary: >-
FGFR2 is critical for cranial skeleton development. Mutations cause
craniosynostosis - premature fusion of cranial sutures.
action: ACCEPT
reason: >-
Strong evidence from human genetics - FGFR2 mutations cause Crouzon syndrome,
Apert syndrome, Pfeiffer syndrome, and other craniosynostoses.
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:10618369
review:
summary: >-
PMID:10618369 is a structural study of FGFR2-FGF1 complex. The term
"protein binding" is uninformative - more specific terms like "fibroblast
growth factor binding" are available and preferred.
action: MODIFY
reason: >-
"Protein binding" is too generic for GO annotation. This paper documents
FGF binding which is already captured by GO:0017134.
proposed_replacement_terms:
- id: GO:0017134
label: fibroblast growth factor binding
supported_by:
- reference_id: PMID:10618369
supporting_text: Structural interactions of fibroblast growth factor
receptor with its ligands.
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:10830168
review:
summary: >-
PMID:10830168 reports crystal structures of FGF-FGFR complexes. Shows
determinants of ligand-receptor specificity. "Protein binding" is too generic.
action: MODIFY
reason: >-
Paper specifically documents FGF binding. Should use GO:0017134 fibroblast
growth factor binding instead.
proposed_replacement_terms:
- id: GO:0017134
label: fibroblast growth factor binding
supported_by:
- reference_id: PMID:10830168
supporting_text: Crystal structures of two FGF-FGFR complexes reveal
the determinants of ligand-receptor specificity.
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:11390973
review:
summary: >-
PMID:11390973 describes structural basis for FGFR2 activation in Apert
syndrome, examining FGF2 binding. "Protein binding" is too generic.
action: MODIFY
reason: >-
Paper documents FGF2 binding to FGFR2. Should use more specific term.
proposed_replacement_terms:
- id: GO:0017134
label: fibroblast growth factor binding
supported_by:
- reference_id: PMID:11390973
supporting_text: Structural basis for fibroblast growth factor
receptor 2 activation in Apert syndrome.
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:12591959
review:
summary: >-
PMID:12591959 examines structural basis by which alternative splicing confers
specificity in FGF receptors. Shows FGF10 binding to FGFR2IIIb.
action: MODIFY
reason: >-
Paper documents isoform-specific FGF binding. Should use GO:0017134.
proposed_replacement_terms:
- id: GO:0017134
label: fibroblast growth factor binding
supported_by:
- reference_id: PMID:12591959
supporting_text: Structural basis by which alternative splicing
confers specificity in fibroblast growth factor receptors.
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:1309608
review:
summary: >-
PMID:1309608 is a seminal paper showing that alternative splicing creates
two distinct growth factor receptors with different ligand specificities.
Documents FGF1 and FGF7 binding differences between isoforms.
action: MODIFY
reason: >-
Classic paper on FGFR2 isoform-specific FGF binding. Should use GO:0017134.
proposed_replacement_terms:
- id: GO:0017134
label: fibroblast growth factor binding
supported_by:
- reference_id: PMID:1309608
supporting_text: 'Determination of ligand-binding specificity by alternative
splicing: two distinct growth factor receptors encoded by a single gene.'
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:22726438
review:
summary: >-
PMID:22726438 documents inhibition of basal FGF receptor signaling by
dimeric Grb2. Shows GRB2 interaction with FGFR2.
action: MODIFY
reason: >-
Documents specific GRB2 binding. Should be annotated with a more specific
term reflecting signaling adaptor interaction.
proposed_replacement_terms:
- id: GO:0005068
label: transmembrane receptor protein tyrosine kinase adaptor activity
supported_by:
- reference_id: PMID:22726438
supporting_text: Inhibition of basal FGF receptor signaling by dimeric
Grb2.
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:23597563
review:
summary: >-
PMID:23597563 describes molecular mechanism of SSR128129E, an extracellularly
acting small-molecule allosteric inhibitor. Documents drug-receptor interaction.
action: MARK_AS_OVER_ANNOTATED
reason: >-
This paper is about drug binding, not protein-protein interaction. The
"protein binding" annotation does not capture meaningful biology here.
supported_by:
- reference_id: PMID:23597563
supporting_text: Molecular mechanism of SSR128129E, an extracellularly
acting, small-molecule, allosteric inhibitor of FGF receptor
signaling.
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:25241761
review:
summary: >-
PMID:25241761 uses in situ proximity ligation assay to profile endogenous
protein-protein interactions. High-throughput interactome study.
action: MARK_AS_OVER_ANNOTATED
reason: >-
High-throughput study without specific functional characterization. "Protein
binding" is too generic to be informative.
supported_by:
- reference_id: PMID:25241761
supporting_text: Oct 9. Using an in situ proximity ligation assay to
systematically profile endogenous protein-protein interactions in a
pathway network.
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:26267536
review:
summary: >-
PMID:26267536 describes long-pentraxin 3 derivative as FGF trap for cancer
therapy. Documents FGF sequestration rather than receptor binding.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Paper focuses on therapeutic FGF trapping, not native FGFR2 interactions.
"Protein binding" is not informative here.
supported_by:
- reference_id: PMID:26267536
supporting_text: Long-Pentraxin 3 Derivative as a Small-Molecule FGF
Trap for Cancer Therapy.
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:33961781
review:
summary: >-
PMID:33961781 is a large-scale proteome study of the human interactome.
High-throughput data without specific functional characterization.
action: MARK_AS_OVER_ANNOTATED
reason: >-
High-throughput interactome study. "Protein binding" is too generic to be
informative for specific gene annotation.
supported_by:
- reference_id: PMID:33961781
supporting_text: 2021 May 6. Dual proteome-scale networks reveal
cell-specific remodeling of the human interactome.
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:35384245
review:
summary: >-
PMID:35384245 is a physical interactome atlas of human receptor tyrosine
kinases. Large-scale study of RTK interactions.
action: MARK_AS_OVER_ANNOTATED
reason: >-
High-throughput interactome study. Generic "protein binding" annotations
from such studies add little value.
supported_by:
- reference_id: PMID:35384245
supporting_text: Physical and functional interactome atlas of human
receptor tyrosine kinases.
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:35922511
review:
summary: >-
PMID:35922511 is a physical wiring diagram for the human immune system.
Large-scale protein interaction study.
action: MARK_AS_OVER_ANNOTATED
reason: >-
High-throughput study. Generic "protein binding" from such studies is
not informative for specific gene function.
supported_by:
- reference_id: PMID:35922511
supporting_text: Aug 3. A physical wiring diagram for the human immune
system.
- term:
id: GO:0001837
label: epithelial to mesenchymal transition
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
ISOFORM-SPECIFIC CONCERN: FGFR2 isoform switching (IIIb to IIIc) is
associated with EMT. IIIb is epithelial; IIIc is mesenchymal. This
annotation conflates gene-level with isoform-specific biology.
action: KEEP_AS_NON_CORE
reason: >-
The isoform switch from IIIb to IIIc accompanies EMT in cancer, but FGFR2
itself does not directly cause EMT. This is a correlative rather than
causative role. The annotation may be valid but represents secondary biology.
- term:
id: GO:0003416
label: endochondral bone growth
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
FGFR2 plays a role in bone development. Mutations cause craniosynostosis
and affect skeletal growth.
action: ACCEPT
reason: >-
Valid bone development function supported by disease phenotypes. UniProt
documents FGFR2 role in osteogenesis and skeletal development.
- term:
id: GO:0009986
label: cell surface
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
FGFR2 is a cell surface receptor. More specific than plasma membrane in
indicating the exposed surface.
action: ACCEPT
reason: >-
Valid localization. FGFR2 is a transmembrane receptor exposed at the cell
surface for ligand binding.
- term:
id: GO:0017134
label: fibroblast growth factor binding
evidence_type: IEA
original_reference_id: GO_REF:0000120
review:
summary: >-
Duplicate of IBA annotation. FGF binding is a core FGFR2 function.
action: ACCEPT
reason: >-
Core function - duplicates IBA with different evidence.
- term:
id: GO:0032496
label: response to lipopolysaccharide
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
LPS response is not a characterized FGFR2 function. This annotation may
reflect expression changes rather than direct function.
action: MARK_AS_OVER_ANNOTATED
reason: >-
No clear evidence that FGFR2 has a direct role in LPS response. This is
likely an ortholog transfer from expression data rather than functional data.
- term:
id: GO:0044344
label: cellular response to fibroblast growth factor stimulus
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
FGFR2 mediates cellular response to FGF. This is its core function as an
FGF receptor.
action: ACCEPT
reason: >-
Core function. FGFR2 is the receptor that mediates cellular response to
multiple FGFs.
- term:
id: GO:0045471
label: response to ethanol
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
Ethanol response is not a characterized FGFR2 function. This annotation
likely reflects expression changes rather than direct function.
action: MARK_AS_OVER_ANNOTATED
reason: >-
No evidence that FGFR2 has a direct role in ethanol response. Likely
ortholog transfer from expression data.
- term:
id: GO:0048333
label: mesodermal cell differentiation
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
FGFR2IIIc (mesenchymal isoform) is involved in mesenchymal/mesodermal cell
biology. This annotation may be partially isoform-specific.
action: ACCEPT
reason: >-
Valid for FGFR2IIIc isoform specifically. FGF signaling through IIIc supports
mesenchymal cell differentiation.
- term:
id: GO:0050680
label: negative regulation of epithelial cell proliferation
evidence_type: IEA
original_reference_id: GO_REF:0000120
review:
summary: >-
This annotation seems contradictory to FGFR2's known role in promoting
keratinocyte (epithelial) proliferation. The annotation may be context-
specific or erroneous.
action: UNDECIDED
reason: >-
UniProt states FGFR2 "promotes cell proliferation in keratinocytes" which
contradicts negative regulation. May apply to specific contexts but unclear.
- term:
id: GO:0071300
label: cellular response to retinoic acid
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
Retinoic acid response is not a characterized FGFR2 function. May reflect
expression regulation rather than functional response.
action: MARK_AS_OVER_ANNOTATED
reason: >-
No clear evidence for direct FGFR2 role in retinoic acid response. Likely
ortholog transfer from expression data.
- term:
id: GO:0071456
label: cellular response to hypoxia
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
Hypoxia response is not a well-characterized FGFR2 function. May reflect
expression changes in hypoxia.
action: MARK_AS_OVER_ANNOTATED
reason: >-
No clear evidence for direct FGFR2 role in hypoxia response. Likely ortholog
transfer from expression data.
- term:
id: GO:0071560
label: cellular response to transforming growth factor beta stimulus
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
TGF-beta response may involve FGFR2 in certain contexts, especially related
to EMT where both pathways interact.
action: KEEP_AS_NON_CORE
reason: >-
There is crosstalk between FGF and TGF-beta pathways in EMT and development,
but this is not a primary FGFR2 function.
- term:
id: GO:1904707
label: positive regulation of vascular associated smooth muscle cell
proliferation
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
FGF signaling can promote smooth muscle cell proliferation, potentially via
FGFR2IIIc in mesenchymal cells.
action: KEEP_AS_NON_CORE
reason: >-
Valid but not a primary FGFR2 function. FGF2 signaling through FGFR can
promote VSMC proliferation but this is not unique to FGFR2.
- term:
id: GO:0009986
label: cell surface
evidence_type: IDA
original_reference_id: PMID:17959718
review:
summary: >-
PMID:17959718 examines heparanase cleavage of perlecan and FGF10 activity
in submandibular gland branching morphogenesis. Shows FGFR2 at cell surface.
action: ACCEPT
reason: >-
Direct experimental evidence for cell surface localization during
FGF10-FGFR2 signaling in branching morphogenesis.
supported_by:
- reference_id: PMID:17959718
supporting_text: Heparanase cleavage of perlecan heparan sulfate
modulates FGF10 activity during ex vivo submandibular gland
branching morphogenesis.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654748
review:
summary: >-
Reactome pathway annotation. Multiple Reactome entries document FGFR2
plasma membrane localization in various signaling contexts.
action: ACCEPT
reason: >-
Plasma membrane localization is well established for transmembrane FGFR2
isoforms. Reactome pathway data supports this.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5655233
review:
summary: >-
Reactome pathway annotation for FGFR2 signaling. Duplicates other PM annotations.
action: ACCEPT
reason: >-
Valid localization, consistent with other evidence.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5655241
review:
summary: >-
Reactome pathway annotation. Part of FGFR2 signaling pathway documentation.
action: ACCEPT
reason: >-
Valid localization, consistent with other evidence.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5655245
review:
summary: >-
Reactome pathway annotation for FGFR2 at plasma membrane.
action: ACCEPT
reason: >-
Valid localization, duplicates other evidence.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5655268
review:
summary: >-
Reactome pathway annotation for FGFR2 signaling.
action: ACCEPT
reason: >-
Valid localization, consistent with established biology.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5655301
review:
summary: >-
Reactome pathway annotation for FGFR2 signaling.
action: ACCEPT
reason: >-
Valid localization.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5655320
review:
summary: >-
Reactome pathway annotation for FGFR2 signaling.
action: ACCEPT
reason: >-
Valid localization.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5655323
review:
summary: >-
Reactome pathway annotation for FGFR2 signaling.
action: ACCEPT
reason: >-
Valid localization.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5655339
review:
summary: >-
Reactome pathway annotation for FGFR2 signaling.
action: ACCEPT
reason: >-
Valid localization.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5655343
review:
summary: >-
Reactome pathway annotation for FGFR2 signaling.
action: ACCEPT
reason: >-
Valid localization.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-8853313
review:
summary: >-
Reactome pathway annotation for FGFR2 fusions autophosphorylation. Documents
aberrant signaling in cancer.
action: ACCEPT
reason: >-
Valid localization for wild-type and fusion FGFR2.
- term:
id: GO:0010839
label: negative regulation of keratinocyte proliferation
evidence_type: IMP
original_reference_id: PMID:21412257
review:
summary: >-
PMID:21412257 shows miR-125b modulates keratinocyte proliferation by
targeting FGFR2. Knockdown of FGFR2 by miRNA reduces proliferation,
suggesting FGFR2 normally promotes (not inhibits) keratinocyte proliferation.
action: REMOVE
reason: >-
This annotation appears incorrect. The paper shows that FGFR2 knockdown
reduces keratinocyte proliferation, meaning FGFR2 positively regulates
proliferation. The annotation should be GO:0050679 (positive regulation
of epithelial cell proliferation) rather than negative regulation.
supported_by:
- reference_id: PMID:21412257
supporting_text: Mar 17. MiR-125b, a microRNA downregulated in
psoriasis, modulates keratinocyte proliferation by targeting FGFR2.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-8853319
review:
summary: >-
Reactome pathway annotation for plasma membrane localization. FGFR2
transmembrane isoforms are plasma membrane receptors. Multiple Reactome
pathways include FGFR2 at the plasma membrane.
action: ACCEPT
reason: >-
Correct localization for transmembrane FGFR2 isoforms. Duplicate entries
from different Reactome pathways reflect FGFR2 participation in multiple
signaling contexts at the plasma membrane.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-2029989
review:
summary: >-
Reactome pathway annotation duplicate. Plasma membrane localization is
well established for transmembrane FGFR2 isoforms.
action: ACCEPT
reason: >-
Duplicate of other plasma membrane annotations from different Reactome
pathway contexts. Valid for transmembrane isoforms.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-2029983
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-2029984
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-2033472
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-2033474
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-2033479
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-2033486
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-2033488
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-2033490
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-2077424
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-109699
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-190413
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-2316434
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-2400009
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654147
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654157
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654159
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654397
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654399
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654402
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654404
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654406
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654407
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654562
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654603
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654605
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654607
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654608
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654612
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654614
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654615
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654618
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654620
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654622
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654677
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654697
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654701
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5654729
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5672965
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-190258
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-190260
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-190408
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-NUL-8853328
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-2029988
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-2029992
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: TAS
original_reference_id: Reactome:R-HSA-2067713
review:
summary: >-
Reactome pathway annotation duplicate for plasma membrane localization.
action: ACCEPT
reason: >-
Valid duplicate annotation from different Reactome pathway.
- term:
id: GO:0048701
label: embryonic cranial skeleton morphogenesis
evidence_type: IMP
original_reference_id: PMID:7874170
review:
summary: >-
Mutations in FGFR2 cause Jackson-Weiss and Crouzon syndromes, which feature
craniosynostosis (premature fusion of cranial sutures). This demonstrates
FGFR2 role in cranial skeleton development. PMID:7874170 identified FGFR2
mutations in the IIIc domain in Jackson-Weiss syndrome families.
action: ACCEPT
reason: >-
Strong genetic evidence linking FGFR2 mutations to craniosynostosis syndromes.
FGFR2 is essential for normal cranial suture development; gain-of-function
mutations cause premature suture fusion. This is a well-established core
developmental function particularly for the IIIc isoform in mesenchyme.
supported_by:
- reference_id: PMID:7874170
supporting_text: "We now report an FGFR2 mutation in the conserved region
of the immunoglobulin IIIc domain in the Jackson-Weiss syndrome family
in which the syndrome was originally described."
- term:
id: GO:0048701
label: embryonic cranial skeleton morphogenesis
evidence_type: IMP
original_reference_id: PMID:7987400
review:
summary: >-
PMID:7987400 demonstrates that mutations in FGFR2 cause Crouzon syndrome,
providing additional genetic evidence for FGFR2 role in cranial skeleton
development. Multiple mutations in the B exon (IIIc domain) were identified.
action: ACCEPT
reason: >-
Complements PMID:7874170 evidence. Crouzon syndrome is autosomal dominant
craniosynostosis caused by FGFR2 mutations, including cysteine substitutions
in the Ig-like domain. Core developmental function.
supported_by:
- reference_id: PMID:7987400
supporting_text: "We now present evidence that mutations in the fibroblast
growth factor receptor 2 gene (FGFR2) cause Crouzon syndrome."
- term:
id: GO:0005634
label: nucleus
evidence_type: IDA
original_reference_id: PMID:16597614
review:
summary: >-
PMID:16597614 observed FGF-10 receptor (FGFR2IIIb/KGFR) in nucleus of
urothelial cells by microscopy. This is an intriguing finding suggesting
nuclear translocation of activated receptor, though unconventional.
action: KEEP_AS_NON_CORE
reason: >-
Nuclear localization of FGFRs has been reported but is non-canonical and
represents a specialized signaling mechanism rather than the primary
localization. The main function of FGFR2 is at the plasma membrane.
supported_by:
- reference_id: PMID:16597614
supporting_text: "Deconvolution, light and transmission electron microscopic
studies captured FGF-10 and its receptor in association with the urothelial
cell surface, in cytoplasm, and within nuclei"
- term:
id: GO:0005737
label: cytoplasm
evidence_type: IDA
original_reference_id: PMID:16597614
review:
summary: >-
PMID:16597614 showed FGFR2 (FGF-10 receptor) localizes to cytoplasm during
its trafficking and signaling in urothelial cells.
action: ACCEPT
reason: >-
FGFR2 is found in cytoplasm during biosynthesis, trafficking to plasma
membrane, and after receptor internalization. Valid localization.
supported_by:
- reference_id: PMID:16597614
supporting_text: "Deconvolution, light and transmission electron microscopic
studies captured FGF-10 and its receptor in association with the urothelial
cell surface, in cytoplasm, and within nuclei"
- term:
id: GO:0009986
label: cell surface
evidence_type: IDA
original_reference_id: PMID:16597614
review:
summary: >-
PMID:16597614 localized FGFR2 (FGF-10 receptor) to the urothelial cell
surface, consistent with its function as a transmembrane receptor.
action: ACCEPT
reason: >-
Cell surface localization is expected for transmembrane receptor tyrosine
kinases. This is functionally equivalent to plasma membrane localization.
supported_by:
- reference_id: PMID:16597614
supporting_text: "Deconvolution, light and transmission electron microscopic
studies captured FGF-10 and its receptor in association with the urothelial
cell surface"
- term:
id: GO:0005007
label: fibroblast growth factor receptor activity
evidence_type: IDA
original_reference_id: PMID:15629145
review:
summary: >-
PMID:15629145 studied KGFR (FGFR2IIIb) signaling through autophosphorylation
and downstream pathway activation. The study demonstrated functional FGF
receptor activity through tyrosine phosphorylation assays.
action: ACCEPT
reason: >-
Direct experimental demonstration of FGFR2 (KGFR isoform) receptor activity
including autophosphorylation and signaling. Core molecular function.
supported_by:
- reference_id: PMID:15629145
supporting_text: "KGFR is rapidly autophosphorylated on specific tyrosine
residues in the intracellular domain, recruits substrate proteins"
- term:
id: GO:0005007
label: fibroblast growth factor receptor activity
evidence_type: IDA
original_reference_id: PMID:8663044
review:
summary: >-
PMID:8663044 systematically tested FGF receptor splice variants for ligand
specificity and mitogenic activity. This landmark study established FGFR2
isoform-specific ligand binding and receptor activation.
action: ACCEPT
reason: >-
Comprehensive biochemical characterization of FGFR2 splice variants as
functional FGF receptors. Demonstrated mitogenic activity with multiple
FGF ligands. Foundational study for FGFR2 biology.
supported_by:
- reference_id: PMID:8663044
supporting_text: "we have engineered mitogenically responsive cell lines
expressing the major splice variants of all the known FGF receptors. We
have assayed the mitogenic activity of the nine known FGF ligands on these
cell lines."
- term:
id: GO:0005886
label: plasma membrane
evidence_type: IDA
original_reference_id: PMID:15629145
review:
summary: >-
PMID:15629145 studied KGFR (FGFR2IIIb) at the plasma membrane where it
undergoes ligand-induced internalization.
action: ACCEPT
reason: >-
Plasma membrane localization is the primary site of FGFR2 function as a
transmembrane receptor.
supported_by:
- reference_id: PMID:15629145
supporting_text: Tyrosine 769 of the keratinocyte growth factor
receptor is required for receptor signaling but not endocytosis.
- term:
id: GO:0005886
label: plasma membrane
evidence_type: IDA
original_reference_id: PMID:16844695
review:
summary: >-
PMID:16844695 studied FGFR2 trafficking and localization, showing wild-type
FGFR2 localizes to plasma membrane while glycosylation-deficient and
mutant forms show altered localization.
action: ACCEPT
reason: >-
Demonstrates plasma membrane is the normal localization for properly
processed FGFR2, while mutations affecting glycosylation impair trafficking.
supported_by:
- reference_id: PMID:16844695
supporting_text: "we show that trafficking and autoactivation of wild type
FGFR2 is glycosylation-dependent"
- term:
id: GO:0008284
label: positive regulation of cell population proliferation
evidence_type: IMP
original_reference_id: PMID:15629145
review:
summary: >-
PMID:15629145 showed that KGFR Y769F mutation impairs cell proliferation,
demonstrating that functional KGFR (FGFR2IIIb) signaling promotes
proliferation.
action: ACCEPT
reason: >-
Mutant phenotype analysis demonstrates FGFR2 promotes cell proliferation.
Core biological process for FGFR signaling.
supported_by:
- reference_id: PMID:15629145
supporting_text: "tyrosine 769 is required...for cell proliferation through
the regulation of FRS2 tyrosine phosphorylation"
- term:
id: GO:0008284
label: positive regulation of cell population proliferation
evidence_type: IDA
original_reference_id: PMID:8663044
review:
summary: >-
PMID:8663044 used mitogenic assays to demonstrate FGF-induced proliferation
through FGFR2. Multiple FGF ligands activated FGFR2-expressing cells.
action: ACCEPT
reason: >-
Direct mitogenic assays showing FGFR2 activation promotes cell proliferation.
Foundational evidence for this core biological process.
supported_by:
- reference_id: PMID:8663044
supporting_text: Receptor specificity of the fibroblast growth factor
family.
- term:
id: GO:0008543
label: fibroblast growth factor receptor signaling pathway
evidence_type: IDA
original_reference_id: PMID:15629145
review:
summary: >-
PMID:15629145 characterized KGFR signaling pathway including PLCgamma
recruitment, FRS2 phosphorylation, and MAPK activation. This directly
demonstrates FGF receptor signaling.
action: ACCEPT
reason: >-
Detailed characterization of FGFR2 (KGFR) signaling pathway components.
Core biological process.
supported_by:
- reference_id: PMID:15629145
supporting_text: "tyrosine 769 is required for the binding to KGFR and tyrosine
phosphorylation of PLCgamma as well as for the full activation of MAPKs"
- term:
id: GO:0008543
label: fibroblast growth factor receptor signaling pathway
evidence_type: IDA
original_reference_id: PMID:8663044
review:
summary: >-
PMID:8663044 demonstrated FGF signaling through FGFR2 using mitogenic
assays as readout of pathway activation.
action: ACCEPT
reason: >-
Functional demonstration of FGF signaling pathway activation through FGFR2.
supported_by:
- reference_id: PMID:8663044
supporting_text: Receptor specificity of the fibroblast growth factor
family.
- term:
id: GO:0010518
label: positive regulation of phospholipase activity
evidence_type: IMP
original_reference_id: PMID:16844695
review:
summary: >-
PMID:16844695 showed both wild-type and mutant FGFR2 signal through PLCgamma.
The C278F mutation and unglycosylated FGFR2 signal through PLCgamma in a
ligand-independent manner.
action: ACCEPT
reason: >-
Demonstrates FGFR2 activates PLCgamma (phospholipase C gamma), which is a
well-established downstream effector of FGFR signaling.
supported_by:
- reference_id: PMID:16844695
supporting_text: "Both FGFR2C278F and unglycosylated wild type FGFR2 signal
through phospholipase Cgamma in a ligand-independent manner"
- term:
id: GO:0017134
label: fibroblast growth factor binding
evidence_type: IDA
original_reference_id: PMID:8663044
review:
summary: >-
PMID:8663044 systematically characterized FGF binding specificity of FGFR2
splice variants. FGF1 binds all variants; FGF2 binds IIIc; FGF7 binds IIIb.
action: ACCEPT
reason: >-
Comprehensive biochemical characterization of FGF binding to FGFR2 isoforms.
Core molecular function. Established isoform-specific ligand preferences.
supported_by:
- reference_id: PMID:8663044
supporting_text: "FGF 1 is the only FGF that can activate all FGF receptor
splice variants"
- term:
id: GO:0018108
label: peptidyl-tyrosine phosphorylation
evidence_type: IDA
original_reference_id: PMID:15629145
review:
summary: >-
PMID:15629145 demonstrated KGFR (FGFR2IIIb) phosphorylates tyrosine residues
on PLCgamma and FRS2 substrates. The study showed Y769 is required for
PLCgamma and FRS2 tyrosine phosphorylation.
action: ACCEPT
reason: >-
Direct demonstration of FGFR2 tyrosine kinase activity phosphorylating
substrates. Core enzymatic function of receptor tyrosine kinases.
supported_by:
- reference_id: PMID:15629145
supporting_text: "tyrosine 769 is required for the binding to KGFR and tyrosine
phosphorylation of PLCgamma...through the regulation of FRS2 tyrosine
phosphorylation"
- term:
id: GO:0018108
label: peptidyl-tyrosine phosphorylation
evidence_type: IDA
original_reference_id: PMID:16844695
review:
summary: >-
PMID:16844695 showed FGFR2 phosphorylates itself and downstream substrates.
Both wild-type and mutant FGFR2 exhibit tyrosine phosphorylation activity.
action: ACCEPT
reason: >-
Confirms FGFR2 tyrosine kinase activity in phosphorylating substrates.
supported_by:
- reference_id: PMID:16844695
supporting_text: 2006 Jul 14. Intracellular retention, degradation,
and signaling of glycosylation-deficient FGFR2 and craniosynostosis
syndrome-associated FGFR2C278F.
- term:
id: GO:0033688
label: regulation of osteoblast proliferation
evidence_type: TAS
original_reference_id: PMID:15190072
review:
summary: >-
PMID:15190072 studied FGFR2 S252W gain-of-function mutation in osteoblasts.
The study shows constitutive FGFR2 activation affects osteoblast
proliferation through regulation of Src family kinases Lyn and Fyn.
action: ACCEPT
reason: >-
Direct evidence that FGFR2 regulates osteoblast proliferation. This function
is highly relevant to craniosynostosis syndromes caused by FGFR2 mutations.
supported_by:
- reference_id: PMID:15190072
supporting_text: "Fibroblast growth factors (FGFs) play an important regulatory
role in skeletal development and bone formation"
- term:
id: GO:0042803
label: protein homodimerization activity
evidence_type: IPI
original_reference_id: PMID:16844695
review:
summary: >-
PMID:16844695 studied FGFR2 homodimerization which is required for receptor
activation. FGFR2 dimerizes upon ligand binding or constitutively in
gain-of-function mutants.
action: ACCEPT
reason: >-
FGFR2 homodimerization is essential for receptor activation. Documented
by immunoprecipitation studies. Core mechanism of receptor activation.
supported_by:
- reference_id: PMID:16844695
supporting_text: 2006 Jul 14. Intracellular retention, degradation,
and signaling of glycosylation-deficient FGFR2 and craniosynostosis
syndrome-associated FGFR2C278F.
- term:
id: GO:0043410
label: positive regulation of MAPK cascade
evidence_type: IMP
original_reference_id: PMID:15629145
review:
summary: >-
PMID:15629145 showed that KGFR Y769F mutation impairs MAPK activation,
demonstrating that functional FGFR2 signaling is required for full MAPK
cascade activation.
action: ACCEPT
reason: >-
Mutant phenotype analysis confirms FGFR2 activates MAPK cascade. Core
downstream signaling pathway.
supported_by:
- reference_id: PMID:15629145
supporting_text: "tyrosine 769 is required...for the full activation of
MAPKs"
- term:
id: GO:0045667
label: regulation of osteoblast differentiation
evidence_type: TAS
original_reference_id: PMID:15190072
review:
summary: >-
PMID:15190072 demonstrated that constitutive FGFR2 activation promotes
osteoblast differentiation through Cbl-mediated degradation of Src family
kinases Lyn and Fyn.
action: ACCEPT
reason: >-
Direct evidence that FGFR2 regulates osteoblast differentiation. The
FGFR2 S252W mutation (Apert syndrome) increases ALP expression, a marker
of osteoblast differentiation.
supported_by:
- reference_id: PMID:15190072
supporting_text: "constitutive FGFR2 activation induces c-Cbl-dependent
Lyn and Fyn proteasome degradation, resulting in...increased ALP expression"
- term:
id: GO:0046777
label: protein autophosphorylation
evidence_type: IDA
original_reference_id: PMID:15629145
review:
summary: >-
PMID:15629145 demonstrated KGFR (FGFR2IIIb) autophosphorylation on tyrosine
residues including Y769 upon ligand binding.
action: ACCEPT
reason: >-
Direct demonstration of FGFR2 autophosphorylation. Core mechanism of
receptor tyrosine kinase activation.
supported_by:
- reference_id: PMID:15629145
supporting_text: "KGFR is rapidly autophosphorylated on specific tyrosine
residues in the intracellular domain"
- term:
id: GO:0048705
label: skeletal system morphogenesis
evidence_type: TAS
original_reference_id: PMID:15190072
review:
summary: >-
PMID:15190072 discusses FGFR2 role in skeletal development. FGFR2 mutations
cause skeletal abnormalities including craniosynostosis.
action: ACCEPT
reason: >-
FGFR2 is essential for skeletal system development. Mutations cause
multiple craniosynostosis syndromes affecting skull development.
supported_by:
- reference_id: PMID:15190072
supporting_text: "Fibroblast growth factors (FGFs) play an important regulatory
role in skeletal development and bone formation"
- term:
id: GO:0035602
label: fibroblast growth factor receptor signaling pathway involved in
negative regulation of apoptotic process in bone marrow cell
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation transferred from mouse ortholog. Overly specific term for
a context-dependent function that is not a primary role for human FGFR2.
action: MARK_AS_OVER_ANNOTATED
reason: >-
While FGF signaling can have anti-apoptotic effects, this highly specific
term (bone marrow cell apoptosis) is not a core function of human FGFR2.
Mouse knockout data may not directly translate to primary human function.
- term:
id: GO:0035603
label: fibroblast growth factor receptor signaling pathway involved in
hemopoiesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation transferred from mouse ortholog. Hemopoiesis is not a primary
function of FGFR2; this likely reflects pleiotropic effects in mouse models.
action: MARK_AS_OVER_ANNOTATED
reason: >-
FGFR2 primary functions are in epithelial-mesenchymal signaling, skeletal
development, and wound healing. Hemopoietic role is not a core function.
- term:
id: GO:0035604
label: fibroblast growth factor receptor signaling pathway involved in
positive regulation of cell proliferation in bone marrow
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation transferred from mouse ortholog. Overly specific term for
bone marrow context that is not a primary FGFR2 function.
action: MARK_AS_OVER_ANNOTATED
reason: >-
While FGFR2 promotes proliferation generally, this bone marrow-specific
context is not a core function for human FGFR2.
- term:
id: GO:0035607
label: fibroblast growth factor receptor signaling pathway involved in
orbitofrontal cortex development
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2 has roles in brain development
but this specific term for orbitofrontal cortex is highly specialized.
action: KEEP_AS_NON_CORE
reason: >-
Brain development role is plausible given FGFR2 mutations cause Crouzon
and Apert syndromes which can have CNS effects. However, this is a very
specific developmental context, not a core function.
- term:
id: GO:0021769
label: orbitofrontal cortex development
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog for orbitofrontal cortex development.
Related to the above signaling pathway annotation.
action: KEEP_AS_NON_CORE
reason: >-
Specialized developmental context. FGFR2 contributes to brain development
but this specific region is not a core function.
- term:
id: GO:0021847
label: ventricular zone neuroblast division
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog for neural progenitor division in the
ventricular zone during brain development.
action: KEEP_AS_NON_CORE
reason: >-
FGF signaling has roles in neural development but this is a specialized
developmental function, not a core FGFR2 function.
- term:
id: GO:0021860
label: pyramidal neuron development
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog for pyramidal neuron development.
action: KEEP_AS_NON_CORE
reason: >-
Specialized neuronal development context. Not a primary FGFR2 function.
- term:
id: GO:0045787
label: positive regulation of cell cycle
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2 promotes cell proliferation which
involves positive regulation of the cell cycle.
action: ACCEPT
reason: >-
Consistent with FGFR2 role in promoting cell proliferation. Mitogenic
signaling through FRS2/MAPK pathway drives cell cycle progression.
- term:
id: GO:0060076
label: excitatory synapse
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog suggesting FGFR2 localization at
excitatory synapses. Unusual localization for a growth factor receptor.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Synaptic localization is not a core function of FGFR2. May reflect
specialized neuronal signaling in mouse models but not a primary
human FGFR2 function.
- term:
id: GO:0000122
label: negative regulation of transcription by RNA polymerase II
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. Indirect effect of FGFR2 signaling
on transcription through downstream pathways.
action: KEEP_AS_NON_CORE
reason: >-
FGFR2 signaling can affect transcription through MAPK and other pathways,
but transcriptional regulation is an indirect downstream effect, not
a core molecular function of the receptor.
- term:
id: GO:0001525
label: angiogenesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. Duplicate of IBA annotation - FGF
signaling has documented roles in angiogenesis.
action: KEEP_AS_NON_CORE
reason: >-
Consistent with IBA annotation. Angiogenesis is a documented but non-core
function for FGFR2; FGFR1 may be more prominent in vascular biology.
- term:
id: GO:0001657
label: ureteric bud development
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2 has roles in kidney development
including ureteric bud branching morphogenesis.
action: KEEP_AS_NON_CORE
reason: >-
UniProt notes FGFR2 is required for normal embryonic patterning including
organogenesis. Kidney development is a documented but tissue-specific
developmental function.
- term:
id: GO:0001701
label: in utero embryonic development
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2 is required for normal embryonic
development as evidenced by embryonic lethality in knockout mice.
action: KEEP_AS_NON_CORE
reason: >-
Very broad developmental term. FGFR2 is essential for development but
more specific terms (limb, lung, skeletal) better capture core functions.
- term:
id: GO:0002053
label: positive regulation of mesenchymal cell proliferation
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2IIIc (mesenchymal isoform) promotes
mesenchymal cell proliferation in response to FGF2/4 from epithelium.
action: ACCEPT
reason: >-
Core function for FGFR2IIIc isoform. Mesenchymal proliferation is central
to epithelial-mesenchymal signaling that FGFR2 mediates in development.
- term:
id: GO:0003148
label: outflow tract septum morphogenesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. Cardiac outflow tract development
involves FGFR signaling but is a specialized developmental context.
action: KEEP_AS_NON_CORE
reason: >-
Cardiac development role is documented for FGFRs but this specific
structure is not a core FGFR2 function.
- term:
id: GO:0003149
label: membranous septum morphogenesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. Cardiac septum development is a
specialized developmental context.
action: KEEP_AS_NON_CORE
reason: >-
Specialized cardiac developmental function, not a core FGFR2 function.
- term:
id: GO:0007267
label: cell-cell signaling
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2 mediates paracrine signaling
between epithelium and mesenchyme.
action: ACCEPT
reason: >-
Core function. FGFR2 mediates paracrine FGF signaling between cell types,
particularly epithelial-mesenchymal communication where IIIb receives
signals from mesenchyme and IIIc receives signals from epithelium.
- term:
id: GO:0007409
label: axonogenesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGF signaling has roles in axon
guidance and neuronal development.
action: KEEP_AS_NON_CORE
reason: >-
Neural development role is documented but not a primary FGFR2 function.
More specialized than core epithelial-mesenchymal signaling roles.
- term:
id: GO:0008589
label: regulation of smoothened signaling pathway
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. Cross-talk between FGF and Hedgehog
(Smoothened) pathways has been reported in development.
action: MARK_AS_OVER_ANNOTATED
reason: >-
While pathway cross-talk exists, direct regulation of Smoothened signaling
is not a core FGFR2 function. This represents indirect developmental
pathway interactions rather than a primary function.
- term:
id: GO:0009791
label: post-embryonic development
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2 has roles in tissue homeostasis
and repair after embryonic development.
action: KEEP_AS_NON_CORE
reason: >-
FGFR2 continues to function in adult tissue homeostasis and wound healing
but this is a broad term. Embryonic roles are better documented.
- term:
id: GO:0009880
label: embryonic pattern specification
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2 contributes to embryonic patterning
through epithelial-mesenchymal interactions.
action: ACCEPT
reason: >-
UniProt confirms FGFR2 is required for normal embryonic patterning. FGF
signaling through FGFR2 establishes tissue boundaries and patterns during
development.
- term:
id: GO:0009887
label: animal organ morphogenesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2 is required for morphogenesis
of multiple organs including limbs, lungs, and skeleton.
action: ACCEPT
reason: >-
Core developmental function. FGFR2 is essential for branching morphogenesis
and organ development, particularly lungs, limbs, and craniofacial skeleton.
- term:
id: GO:0016331
label: morphogenesis of embryonic epithelium
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2IIIb is expressed in epithelium
and receives signals from mesenchyme to direct epithelial morphogenesis.
action: ACCEPT
reason: >-
Core function for FGFR2IIIb isoform. Epithelial morphogenesis through
FGF7/10 signaling is a primary developmental role.
- term:
id: GO:0022612
label: gland morphogenesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2 is required for salivary gland,
lacrimal gland, and other gland development through branching morphogenesis.
action: ACCEPT
reason: >-
Core developmental function. FGFR2-mediated branching morphogenesis is
essential for gland development in multiple organ systems.
- term:
id: GO:0030177
label: positive regulation of Wnt signaling pathway
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. Cross-talk between FGF and Wnt pathways
occurs during development but this is indirect signaling.
action: KEEP_AS_NON_CORE
reason: >-
FGF-Wnt pathway interactions exist during development but positive regulation
of Wnt signaling is not a direct core function of FGFR2.
- term:
id: GO:0030282
label: bone mineralization
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2 regulates osteoblast differentiation
and bone development; mineralization is a downstream effect.
action: KEEP_AS_NON_CORE
reason: >-
Indirect effect of FGFR2 on osteoblast function. The core function is
regulating osteoblast proliferation/differentiation rather than
mineralization per se.
- term:
id: GO:0030324
label: lung development
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2 is essential for lung branching
morphogenesis. UniProt confirms role in lung morphogenesis.
action: ACCEPT
reason: >-
Core developmental function. FGFR2 (particularly IIIb/KGFR) is essential
for lung epithelial branching morphogenesis through FGF10 signaling.
- term:
id: GO:0030855
label: epithelial cell differentiation
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2IIIb in epithelial cells regulates
their differentiation in response to mesenchymal FGF signals.
action: ACCEPT
reason: >-
Core function for FGFR2IIIb isoform. Epithelial differentiation is directed
by FGF7/10 signaling through the epithelial FGFR2 isoform.
- term:
id: GO:0030901
label: midbrain development
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog for midbrain development.
action: KEEP_AS_NON_CORE
reason: >-
Brain development is one of many developmental contexts where FGFR2
functions, but not a primary function.
- term:
id: GO:0030916
label: otic vesicle formation
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog for inner ear development.
action: KEEP_AS_NON_CORE
reason: >-
Specialized developmental context. FGFR2 contributes to ear development
but this is not a core function.
- term:
id: GO:0031069
label: hair follicle morphogenesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2 is required for skin development
including hair follicles. UniProt notes role in skin development.
action: ACCEPT
reason: >-
Documented role in skin development. FGF signaling through FGFR2IIIb
contributes to epithelial appendage formation including hair follicles.
- term:
id: GO:0032808
label: lacrimal gland development
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. Lacrimal gland develops through
branching morphogenesis requiring FGFR2 signaling.
action: KEEP_AS_NON_CORE
reason: >-
Example of gland morphogenesis role. More general gland morphogenesis
term already captures this function.
- term:
id: GO:0035265
label: organ growth
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2 promotes cell proliferation
which contributes to organ growth during development.
action: ACCEPT
reason: >-
General term consistent with FGFR2 role in promoting proliferation
during organ development.
- term:
id: GO:0042472
label: inner ear morphogenesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog for inner ear development.
action: KEEP_AS_NON_CORE
reason: >-
Specialized developmental context for ear morphogenesis.
- term:
id: GO:0042476
label: odontogenesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGF signaling is involved in tooth
development through epithelial-mesenchymal interactions.
action: KEEP_AS_NON_CORE
reason: >-
Tooth development involves FGFR2 but is a specialized developmental
context rather than a core function.
- term:
id: GO:0045165
label: cell fate commitment
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2 signaling influences cell fate
decisions during development.
action: KEEP_AS_NON_CORE
reason: >-
Broad developmental term. FGFR2 influences cell fate but more specific
terms better capture its functions.
- term:
id: GO:0045944
label: positive regulation of transcription by RNA polymerase II
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2 signaling can activate
transcription through MAPK pathway and transcription factors.
action: KEEP_AS_NON_CORE
reason: >-
Indirect downstream effect of FGFR2 signaling rather than a core
molecular function of the receptor.
- term:
id: GO:0048286
label: lung alveolus development
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. Specific aspect of lung development
where FGFR2 contributes to alveolar formation.
action: ACCEPT
reason: >-
Part of core lung development function. FGFR2 is essential for lung
morphogenesis including alveolar development.
- term:
id: GO:0048557
label: embryonic digestive tract morphogenesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog for GI tract development.
action: KEEP_AS_NON_CORE
reason: >-
One of many organs where FGFR2 contributes to development but not
a primary documented function.
- term:
id: GO:0048562
label: embryonic organ morphogenesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. General term for FGFR2 role in
organ development during embryogenesis.
action: ACCEPT
reason: >-
Core developmental function. FGFR2 is essential for morphogenesis of
multiple organs through epithelial-mesenchymal interactions.
- term:
id: GO:0048565
label: digestive tract development
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog for GI tract development.
action: KEEP_AS_NON_CORE
reason: >-
Digestive tract development is one of many developmental contexts.
- term:
id: GO:0048568
label: embryonic organ development
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. Broad term for embryonic
organogenesis role of FGFR2.
action: ACCEPT
reason: >-
Core developmental function consistent with FGFR2 role in multiple
organ systems during development.
- term:
id: GO:0048608
label: reproductive structure development
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog for reproductive organ development.
action: KEEP_AS_NON_CORE
reason: >-
Specialized developmental context not emphasized in human FGFR2 function.
- term:
id: GO:0048730
label: epidermis morphogenesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2 is required for skin
development. UniProt confirms role in skin development.
action: ACCEPT
reason: >-
Documented function. FGFR2IIIb in keratinocytes responds to FGF7/KGF
from dermal fibroblasts to regulate epidermis.
- term:
id: GO:0048755
label: branching morphogenesis of a nerve
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog for nerve branching.
action: KEEP_AS_NON_CORE
reason: >-
Specialized neural context not a primary FGFR2 function.
- term:
id: GO:0048762
label: mesenchymal cell differentiation
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2IIIc in mesenchyme responds
to epithelial FGFs to promote mesenchymal differentiation.
action: ACCEPT
reason: >-
Core function for FGFR2IIIc isoform. Mesenchymal differentiation is
central to FGFR2 role in development.
- term:
id: GO:0050679
label: positive regulation of epithelial cell proliferation
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2IIIb promotes epithelial cell
proliferation in response to FGF7/10. UniProt confirms proliferation
in keratinocytes.
action: ACCEPT
reason: >-
Core function for FGFR2IIIb isoform. Epithelial proliferation is a
primary response to FGF7/10 signaling.
- term:
id: GO:0051150
label: regulation of smooth muscle cell differentiation
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog for smooth muscle differentiation.
action: KEEP_AS_NON_CORE
reason: >-
Specialized context for FGFR2 function in mesenchymal differentiation.
- term:
id: GO:0051781
label: positive regulation of cell division
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2 promotes cell proliferation
which involves cell division.
action: ACCEPT
reason: >-
Consistent with core mitogenic function of FGFR2 signaling.
- term:
id: GO:0055010
label: ventricular cardiac muscle tissue morphogenesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog for cardiac development.
action: KEEP_AS_NON_CORE
reason: >-
Cardiac development context is not a primary FGFR2 function.
- term:
id: GO:0060045
label: positive regulation of cardiac muscle cell proliferation
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog for cardiac muscle proliferation.
action: KEEP_AS_NON_CORE
reason: >-
Specialized cardiac context not a primary FGFR2 function.
- term:
id: GO:0060174
label: limb bud formation
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2 is essential for limb bud
development. UniProt confirms role in limb bud development.
action: ACCEPT
reason: >-
Core developmental function. FGFR2 is required for limb bud outgrowth
and patterning through FGF signaling.
- term:
id: GO:0060348
label: bone development
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2 is essential for bone
development; mutations cause craniosynostosis syndromes.
action: ACCEPT
reason: >-
Core developmental function. FGFR2 mutations in humans cause multiple
skeletal syndromes demonstrating essential role in osteogenesis.
- term:
id: GO:0060349
label: bone morphogenesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2 regulates bone shape through
effects on osteoblast function.
action: ACCEPT
reason: >-
Core function evidenced by craniosynostosis syndromes where FGFR2
mutations cause abnormal skull bone morphology.
- term:
id: GO:0060442
label: branching involved in prostate gland morphogenesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. Prostate gland develops through
branching morphogenesis involving FGFR2.
action: KEEP_AS_NON_CORE
reason: >-
Specific example of branching morphogenesis. General gland morphogenesis
term captures this function.
- term:
id: GO:0060445
label: branching involved in salivary gland morphogenesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. Salivary gland develops through
FGFR2-dependent branching morphogenesis.
action: ACCEPT
reason: >-
Well-documented example of FGFR2-dependent branching morphogenesis.
FGF10/FGFR2IIIb signaling is essential for salivary gland development.
- term:
id: GO:0060449
label: bud elongation involved in lung branching
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. Specific aspect of lung branching
morphogenesis involving bud outgrowth.
action: ACCEPT
reason: >-
Core lung development function. FGF10/FGFR2IIIb signaling drives
epithelial bud elongation in lung branching.
- term:
id: GO:0060463
label: lung lobe morphogenesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog for lung lobe formation.
action: ACCEPT
reason: >-
Part of core lung development function of FGFR2.
- term:
id: GO:0060484
label: lung-associated mesenchyme development
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2IIIc in lung mesenchyme
responds to epithelial FGFs during development.
action: ACCEPT
reason: >-
Core lung development function. Both epithelial (IIIb) and mesenchymal
(IIIc) FGFR2 isoforms contribute to lung development.
- term:
id: GO:0060501
label: positive regulation of epithelial cell proliferation involved in
lung morphogenesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGF10/FGFR2IIIb signaling promotes
lung epithelial proliferation during branching morphogenesis.
action: ACCEPT
reason: >-
Core function for lung development. FGFR2IIIb-mediated epithelial
proliferation is essential for lung morphogenesis.
- term:
id: GO:0060512
label: prostate gland morphogenesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog for prostate development.
action: KEEP_AS_NON_CORE
reason: >-
Specific gland development context. More general gland morphogenesis
captures this function.
- term:
id: GO:0060523
label: prostate epithelial cord elongation
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog for prostate development.
action: KEEP_AS_NON_CORE
reason: >-
Specific prostate developmental context. More general epithelial
morphogenesis and gland development terms capture this function.
- term:
id: GO:0060527
label: prostate epithelial cord arborization involved in prostate
glandular acinus morphogenesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog for highly specific prostate morphogenesis.
action: KEEP_AS_NON_CORE
reason: >-
Overly specific developmental term. General gland morphogenesis captures
FGFR2 role without this level of specificity.
- term:
id: GO:0060529
label: squamous basal epithelial stem cell differentiation involved in
prostate gland acinus development
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog for very specific prostate stem cell context.
action: MARK_AS_OVER_ANNOTATED
reason: >-
Extremely specific term that goes beyond core FGFR2 function. This level
of specificity is not a primary FGFR2 function.
- term:
id: GO:0060601
label: lateral sprouting from an epithelium
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. Epithelial sprouting is part of
branching morphogenesis that FGFR2 mediates.
action: ACCEPT
reason: >-
Consistent with FGFR2 role in branching morphogenesis. Lateral sprouting
is a core mechanism of epithelial branching in lungs and glands.
- term:
id: GO:0060615
label: mammary gland bud formation
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. Mammary gland develops through
FGFR2-dependent mechanisms similar to other glands.
action: KEEP_AS_NON_CORE
reason: >-
Example of gland morphogenesis. General gland development terms capture
this function.
- term:
id: GO:0060664
label: epithelial cell proliferation involved in salivary gland
morphogenesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGF10/FGFR2IIIb signaling promotes
epithelial proliferation in salivary gland development.
action: ACCEPT
reason: >-
Core function for salivary gland development which is a well-documented
FGFR2 function through epithelial-mesenchymal interactions.
- term:
id: GO:0060667
label: branch elongation involved in salivary gland morphogenesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. Branch elongation is a key aspect
of salivary gland branching morphogenesis.
action: ACCEPT
reason: >-
Core salivary gland development function. Consistent with FGFR2 role
in branching morphogenesis.
- term:
id: GO:0060670
label: branching involved in labyrinthine layer morphogenesis
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog for placental labyrinthine layer.
action: KEEP_AS_NON_CORE
reason: >-
Placental development context. UniProt notes trophoblast function but
this specific aspect is not emphasized.
- term:
id: GO:0060688
label: regulation of morphogenesis of a branching structure
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2 is a key regulator of branching
morphogenesis in multiple organs.
action: ACCEPT
reason: >-
Core developmental function. FGFR2 regulates branching morphogenesis in
lungs, glands, and other organs through epithelial-mesenchymal signaling.
- term:
id: GO:0060915
label: mesenchymal cell differentiation involved in lung development
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2IIIc in lung mesenchyme responds
to epithelial signals to regulate mesenchymal differentiation.
action: ACCEPT
reason: >-
Core lung development function. Both epithelial (IIIb) and mesenchymal
(IIIc) FGFR2 isoforms contribute to lung development.
- term:
id: GO:0060916
label: mesenchymal cell proliferation involved in lung development
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2IIIc in lung mesenchyme promotes
proliferation in response to epithelial FGFs.
action: ACCEPT
reason: >-
Core lung development function for FGFR2IIIc isoform.
- term:
id: GO:0070372
label: regulation of ERK1 and ERK2 cascade
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2 activates ERK1/2 (MAPK3/MAPK1)
through the RAS-MAPK pathway.
action: ACCEPT
reason: >-
Core signaling function. ERK1/2 cascade activation is a primary downstream
effect of FGFR2 signaling through FRS2/GRB2/SOS/RAS pathway.
- term:
id: GO:0070374
label: positive regulation of ERK1 and ERK2 cascade
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. FGFR2 positively regulates ERK1/2
cascade activation.
action: ACCEPT
reason: >-
Core signaling function. More specific child term of MAPK cascade
regulation that is well-documented for FGFR2.
- term:
id: GO:0090263
label: positive regulation of canonical Wnt signaling pathway
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from mouse ortholog. Cross-talk between FGF and Wnt
pathways occurs during development.
action: KEEP_AS_NON_CORE
reason: >-
Indirect pathway cross-talk rather than a direct core function of FGFR2.
More specific than general Wnt regulation annotation already reviewed.
- term:
id: GO:0016020
label: membrane
evidence_type: NAS
original_reference_id: PMID:8676562
review:
summary: >-
NAS annotation for membrane localization. FGFR2 is a transmembrane
receptor.
action: ACCEPT
reason: >-
Correct but general term. More specific plasma membrane annotations exist.
supported_by:
- reference_id: PMID:8676562
supporting_text: 'Apert syndrome, acrocephalosyndactyly Type I, is an autosomal
dominant craniosynostosis comprising acrocephaly, facial dysmorphism and
severe syndactyly of the hands and feet.'
- term:
id: GO:0005634
label: nucleus
evidence_type: IDA
original_reference_id: PMID:17471512
review:
summary: >-
PMID:17471512 demonstrated nuclear localization of FGF-10 receptor
(FGFR2IIIb) in urothelial cells along with its ligand FGF-10.
action: KEEP_AS_NON_CORE
reason: >-
Nuclear localization represents a specialized signaling mechanism rather
than the primary localization. Main FGFR2 function is at plasma membrane.
supported_by:
- reference_id: PMID:17471512
supporting_text: "The FGF-10 receptor was observed in cell nuclei regardless
of the presence or concentration of exogenous rFGF-10 ligand"
- term:
id: GO:0005737
label: cytoplasm
evidence_type: IDA
original_reference_id: PMID:17471512
review:
summary: >-
PMID:17471512 showed FGF-10 receptor (FGFR2IIIb) localizes to cytoplasm
in urothelial cells during trafficking.
action: ACCEPT
reason: >-
FGFR2 is found in cytoplasm during biosynthesis, trafficking, and after
internalization.
supported_by:
- reference_id: PMID:17471512
supporting_text: "rFGF-10(no NLS) was found in cytoplasm to a far greater
degree than rFGF-10"
- term:
id: GO:0005938
label: cell cortex
evidence_type: IDA
original_reference_id: PMID:17471512
review:
summary: >-
PMID:17471512 may have observed FGFR2 at the cell cortex during trafficking
or at the plasma membrane interface.
action: KEEP_AS_NON_CORE
reason: >-
Cell cortex localization is not a primary FGFR2 localization. May represent
trafficking intermediate or plasma membrane-associated pool.
supported_by:
- reference_id: PMID:17471512
supporting_text: Translocation of fibroblast growth factor-10 and its
receptor into nuclei of human urothelial cells.
- term:
id: GO:0008284
label: positive regulation of cell population proliferation
evidence_type: IGI
original_reference_id: PMID:8663044
review:
summary: >-
IGI (Inferred from Genetic Interaction) annotation from PMID:8663044 which
tested multiple FGF-FGFR combinations for mitogenic activity.
action: ACCEPT
reason: >-
Consistent with core mitogenic function. PMID:8663044 demonstrated
proliferative activity of FGFR2 with various FGF ligands.
supported_by:
- reference_id: PMID:8663044
supporting_text: Receptor specificity of the fibroblast growth factor
family.
- term:
id: GO:0008543
label: fibroblast growth factor receptor signaling pathway
evidence_type: IGI
original_reference_id: PMID:8663044
review:
summary: >-
IGI annotation from PMID:8663044 demonstrating FGF receptor signaling
through FGFR2.
action: ACCEPT
reason: >-
Core biological process. PMID:8663044 is foundational study for FGFR
signaling specificity.
supported_by:
- reference_id: PMID:8663044
supporting_text: Receptor specificity of the fibroblast growth factor
family.
- term:
id: GO:0005007
label: fibroblast growth factor receptor activity
evidence_type: IGI
original_reference_id: PMID:10830168
review:
summary: >-
IGI annotation from PMID:10830168 which determined crystal structures
of FGF-FGFR complexes and characterized ligand-receptor specificity.
action: ACCEPT
reason: >-
Core molecular function. PMID:10830168 provided structural basis for
FGF receptor specificity through alternative splicing.
supported_by:
- reference_id: PMID:10830168
supporting_text: "Specificity is achieved through interactions between the
N-terminal and central regions of FGFs and two loop regions in D3 that
are subject to alternative splicing"
- term:
id: GO:0008543
label: fibroblast growth factor receptor signaling pathway
evidence_type: IPI
original_reference_id: PMID:10830168
review:
summary: >-
IPI annotation from PMID:10830168 based on physical interaction studies
of FGF-FGFR complexes.
action: ACCEPT
reason: >-
Core signaling pathway. Crystal structures revealed basis for ligand
binding and receptor activation.
supported_by:
- reference_id: PMID:10830168
supporting_text: Crystal structures of two FGF-FGFR complexes reveal
the determinants of ligand-receptor specificity.
- term:
id: GO:0017134
label: fibroblast growth factor binding
evidence_type: IPI
original_reference_id: PMID:8386828
review:
summary: >-
IPI annotation from PMID:8386828 demonstrating FGF-5 binding to FGFR2.
Competition binding studies showed KD of 0.5-1.5 nM.
action: ACCEPT
reason: >-
Core molecular function. Direct binding assays demonstrated FGF binding
to FGFR2 with high affinity.
supported_by:
- reference_id: PMID:8386828
supporting_text: "the KD for FGF-5-FGFR-1 and FGF-5-FGFR-2 interactions
are both between 0.5 and 1.5 x 10(-9) M"
- term:
id: GO:0005007
label: fibroblast growth factor receptor activity
evidence_type: NAS
original_reference_id: PMID:8676562
review:
summary: >-
NAS annotation for FGF receptor activity. Duplicate annotation with
different evidence code.
action: ACCEPT
reason: >-
Core molecular function supported by multiple evidence types.
supported_by:
- reference_id: PMID:8676562
supporting_text: 'Apert syndrome, acrocephalosyndactyly Type I, is an autosomal
dominant craniosynostosis comprising acrocephaly, facial dysmorphism and
severe syndactyly of the hands and feet.'
- term:
id: GO:0004713
label: protein tyrosine kinase activity
evidence_type: NAS
original_reference_id: PMID:1697263
review:
summary: >-
NAS annotation for protein tyrosine kinase activity. FGFR2 is a receptor
tyrosine kinase.
action: ACCEPT
reason: >-
Core molecular function. FGFR2 is a well-characterized receptor tyrosine
kinase (EC 2.7.10.1).
supported_by:
- reference_id: PMID:1697263
supporting_text: Cloning and expression of two distinct high-affinity
receptors cross-reacting with acidic and basic fibroblast growth
factors.
- term:
id: GO:0005007
label: fibroblast growth factor receptor activity
evidence_type: NAS
original_reference_id: PMID:1400433
review:
summary: >-
NAS annotation from PMID:1400433 which identified alternative splicing
creating isoforms with different ligand specificities.
action: ACCEPT
reason: >-
Core molecular function. PMID:1400433 was important for understanding
isoform-specific FGF binding.
supported_by:
- reference_id: PMID:1400433
supporting_text: A novel form of fibroblast growth factor receptor 2.
- term:
id: GO:0005007
label: fibroblast growth factor receptor activity
evidence_type: NAS
original_reference_id: PMID:1697263
review:
summary: >-
NAS annotation for FGF receptor activity. Duplicate with different reference.
action: ACCEPT
reason: >-
Core molecular function.
supported_by:
- reference_id: PMID:1697263
supporting_text: Cloning and expression of two distinct high-affinity
receptors cross-reacting with acidic and basic fibroblast growth
factors.
- term:
id: GO:0016020
label: membrane
evidence_type: NAS
original_reference_id: PMID:1697263
review:
summary: >-
NAS annotation for membrane localization. FGFR2 is a single-pass type I
membrane protein.
action: ACCEPT
reason: >-
Correct but general term. More specific plasma membrane annotations exist.
supported_by:
- reference_id: PMID:1697263
supporting_text: Cloning and expression of two distinct high-affinity
receptors cross-reacting with acidic and basic fibroblast growth
factors.
core_functions:
- molecular_function:
id: GO:0005007
label: fibroblast growth factor receptor activity
directly_involved_in:
- id: GO:0008543
label: fibroblast growth factor receptor signaling pathway
- id: GO:0008284
label: positive regulation of cell population proliferation
- id: GO:0070374
label: positive regulation of ERK1 and ERK2 cascade
- id: GO:0060348
label: bone development
- id: GO:0060688
label: regulation of morphogenesis of a branching structure
- id: GO:0048701
label: embryonic cranial skeleton morphogenesis
- id: GO:0030324
label: lung development
locations:
- id: GO:0005886
label: plasma membrane
references:
- id: file:human/FGFR2/FGFR2-deep-research-falcon.md
title: Deep research report on FGFR2 function, signaling, and clinical relevance
findings:
- statement: >-
FGFR2 is a plasma membrane receptor tyrosine kinase with Ig-like
extracellular domains whose IIIb/IIIc isoform switching determines
epithelial vs mesenchymal ligand specificity.
- statement: >-
Core signaling through FRS2/MAPK and PLCgamma pathways drives
proliferation, differentiation, and branching morphogenesis in lungs,
limbs, skeleton, and glands.
- id: GO_REF:0000002
title: Gene Ontology annotation through association of InterPro records with
GO terms
findings: []
- id: GO_REF:0000003
title: Gene Ontology annotation based on Enzyme Commission mapping
findings: []
- id: GO_REF:0000024
title: Manual transfer of experimentally-verified manual GO annotation data
to orthologs by curator judgment of sequence similarity
findings: []
- id: GO_REF:0000033
title: Annotation inferences using phylogenetic trees
findings: []
- id: GO_REF:0000043
title: Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword
mapping
findings: []
- id: GO_REF:0000044
title: Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular
Location vocabulary mapping, accompanied by conservative changes to GO
terms applied by UniProt
findings: []
- id: GO_REF:0000107
title: Automatic transfer of experimentally verified manual GO annotation
data to orthologs using Ensembl Compara
findings: []
- id: GO_REF:0000117
title: Electronic Gene Ontology annotations created by ARBA machine learning
models
findings: []
- id: GO_REF:0000120
title: Combined Automated Annotation using Multiple IEA Methods
findings: []
- id: PMID:10618369
title: Structural interactions of fibroblast growth factor receptor with its
ligands.
findings: []
- id: PMID:10830168
title: Crystal structures of two FGF-FGFR complexes reveal the determinants
of ligand-receptor specificity.
findings: []
- id: PMID:11390973
title: Structural basis for fibroblast growth factor receptor 2 activation
in Apert syndrome.
findings: []
- id: PMID:12591959
title: Structural basis by which alternative splicing confers specificity in
fibroblast growth factor receptors.
findings: []
- id: PMID:1309608
title: 'Determination of ligand-binding specificity by alternative splicing: two
distinct growth factor receptors encoded by a single gene.'
findings: []
- id: PMID:1400433
title: A novel form of fibroblast growth factor receptor 2. Alternative
splicing of the third immunoglobulin-like domain confers ligand binding
specificity.
findings: []
- id: PMID:15190072
title: Cbl-mediated degradation of Lyn and Fyn induced by constitutive
fibroblast growth factor receptor-2 activation supports osteoblast
differentiation.
findings: []
- id: PMID:15629145
title: Tyrosine 769 of the keratinocyte growth factor receptor is required
for receptor signaling but not endocytosis.
findings: []
- id: PMID:16597614
title: FGF-10 and its receptor exhibit bidirectional paracrine targeting to
urothelial and smooth muscle cells in the lower urinary tract.
findings: []
- id: PMID:16844695
title: Intracellular retention, degradation, and signaling of
glycosylation-deficient FGFR2 and craniosynostosis syndrome-associated
FGFR2C278F.
findings: []
- id: PMID:1697263
title: Cloning and expression of two distinct high-affinity receptors
cross-reacting with acidic and basic fibroblast growth factors.
findings: []
- id: PMID:17471512
title: Translocation of fibroblast growth factor-10 and its receptor into
nuclei of human urothelial cells.
findings: []
- id: PMID:17959718
title: Heparanase cleavage of perlecan heparan sulfate modulates FGF10
activity during ex vivo submandibular gland branching morphogenesis.
findings: []
- id: PMID:21412257
title: MiR-125b, a microRNA downregulated in psoriasis, modulates
keratinocyte proliferation by targeting FGFR2.
findings: []
- id: PMID:22726438
title: Inhibition of basal FGF receptor signaling by dimeric Grb2.
findings: []
- id: PMID:23597563
title: Molecular mechanism of SSR128129E, an extracellularly acting,
small-molecule, allosteric inhibitor of FGF receptor signaling.
findings: []
- id: PMID:25241761
title: Using an in situ proximity ligation assay to systematically profile
endogenous protein-protein interactions in a pathway network.
findings: []
- id: PMID:26267536
title: Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer
Therapy.
findings: []
- id: PMID:33961781
title: Dual proteome-scale networks reveal cell-specific remodeling of the
human interactome.
findings: []
- id: PMID:35384245
title: Physical and functional interactome atlas of human receptor tyrosine
kinases.
findings: []
- id: PMID:35922511
title: A physical wiring diagram for the human immune system.
findings: []
- id: PMID:7874170
title: Jackson-Weiss and Crouzon syndromes are allelic with mutations in
fibroblast growth factor receptor 2.
findings: []
- id: PMID:7987400
title: Mutations in the fibroblast growth factor receptor 2 gene cause
Crouzon syndrome.
findings: []
- id: PMID:8386828
title: Activation of fibroblast growth factor (FGF) receptors by recombinant
human FGF-5.
findings: []
- id: PMID:8663044
title: Receptor specificity of the fibroblast growth factor family.
findings: []
- id: PMID:8676562
title: '[Nucleotide sequences at intron 6 and exon 7 junction of fibroblast growth
factor receptor 2 and rapid mutational analysis in Apert syndrome].'
findings: []
- id: Reactome:R-HSA-109699
title: PI3K-containing complexes phosphorylate PIP2 to PIP3
findings: []
- id: Reactome:R-HSA-190258
title: FGFR2c binds to FGF
findings: []
- id: Reactome:R-HSA-190260
title: FGFR2b binds to FGF
findings: []
- id: Reactome:R-HSA-190408
title: Autocatalytic phosphorylation of FGFR2b
findings: []
- id: Reactome:R-HSA-190413
title: Autocatalytic phosphorylation of FGFR2c
findings: []
- id: Reactome:R-HSA-2029983
title: Dimerization of FGFR2 ligand-independent mutants
findings: []
- id: Reactome:R-HSA-2029984
title: Autocatalytic phosphorylation of FGFR2 ligand-independent mutants
findings: []
- id: Reactome:R-HSA-2029988
title: Dimerization of overexpressed FGFR2
findings: []
- id: Reactome:R-HSA-2029989
title: Autocatalytic phosphorylation of overexpressed FGFR2 variants
findings: []
- id: Reactome:R-HSA-2029992
title: Tyrosine kinase inhibitors bind to overexpressed FGFR2 variants
findings: []
- id: Reactome:R-HSA-2033472
title: FGFR2c mutants bind an expanded range of ligands
findings: []
- id: Reactome:R-HSA-2033474
title: FGFR2b mutants bind an expanded range of ligands
findings: []
- id: Reactome:R-HSA-2033479
title: Dimerization of FGFR2 point mutants with enhanced kinase activity
findings: []
- id: Reactome:R-HSA-2033486
title: Autocatalytic phosphorylation of FGFR2c mutants with enhanced ligand
binding
findings: []
- id: Reactome:R-HSA-2033488
title: Autocatalytic phosphorylation of FGFR2b mutants with enhanced ligand
binding
findings: []
- id: Reactome:R-HSA-2033490
title: Autocatalytic phosphorylation of FGFR2 point mutants with enhanced
kinase activity
findings: []
- id: Reactome:R-HSA-2067713
title: GP369 inhibits activation of amplified FGFR2 signaling
findings: []
- id: Reactome:R-HSA-2077424
title: Point mutants of FGFR2 bind and are inactivated by tyrosine kinase
inhibitors
findings: []
- id: Reactome:R-HSA-2316434
title: PI3K phosphorylates PIP2 to PIP3
findings: []
- id: Reactome:R-HSA-2400009
title: PI3K inhibitors block PI3K catalytic activity
findings: []
- id: Reactome:R-HSA-5654147
title: Activated FGFR2 phosphorylates PLCG1
findings: []
- id: Reactome:R-HSA-5654157
title: p-4Y-PLCG1 dissociates from activated FGFR2
findings: []
- id: Reactome:R-HSA-5654159
title: Activated FGFR2 binds PLCG1
findings: []
- id: Reactome:R-HSA-5654397
title: Activated FGFR2 phosphorylates FRS2
findings: []
- id: Reactome:R-HSA-5654399
title: Activated FGFR2 binds FRS2
findings: []
- id: Reactome:R-HSA-5654402
title: Activated FGFR2:p-SHC1:GRB2:SOS1 activates RAS nucleotide exchange
findings: []
- id: Reactome:R-HSA-5654404
title: Activated FGFR2 binds SHC1
findings: []
- id: Reactome:R-HSA-5654406
title: Activated FGFR2:p-SHC1 binds GRB2:SOS1
findings: []
- id: Reactome:R-HSA-5654407
title: Activated FGFR2 phosphorylates SHC1
findings: []
- id: Reactome:R-HSA-5654562
title: Activated ERK1/2 threonine-phosphorylates FGFR2-associated FRS2
findings: []
- id: Reactome:R-HSA-5654603
title: Activated FGFR2 binds FRS3
findings: []
- id: Reactome:R-HSA-5654605
title: Activated FGFR2 phosphorylates FRS3
findings: []
- id: Reactome:R-HSA-5654607
title: Activated FGFR2 phosphorylates PPTN11
findings: []
- id: Reactome:R-HSA-5654608
title: Activated FGFR2:p-FRS bind to PPTN11
findings: []
- id: Reactome:R-HSA-5654612
title: Activated FGFR2:p-FRS2 binds GRB2:GAB1:PIK3R1
findings: []
- id: Reactome:R-HSA-5654614
title: Activated FGFR2:p-FRS2:GRB2:GAB1:PI3KR1 binds PIK3CA
findings: []
- id: Reactome:R-HSA-5654615
title: Activated FGFR2:pFRS binds GRB2:SOS1
findings: []
- id: Reactome:R-HSA-5654618
title: Activated FGFR2:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange
findings: []
- id: Reactome:R-HSA-5654620
title: Activated FGFR2:p-FRS2:p-PPTN11 binds GRB2:GAB1:PI3KR1
findings: []
- id: Reactome:R-HSA-5654622
title: Activated FGFR2:p-FRS2:p-PPTN11:GRB2:GAB1:PIK3R1 binds PIK3CA
findings: []
- id: Reactome:R-HSA-5654677
title: CBL ubiquitinates FRS2 and FGFR2
findings: []
- id: Reactome:R-HSA-5654697
title: FGFR2- and PTPN11- associated PI3K phosphorylates PIP2 to PIP3
findings: []
- id: Reactome:R-HSA-5654701
title: FGFR2-associated PI3K phosphorylates PIP2 to PIP3
findings: []
- id: Reactome:R-HSA-5654729
title: p-CBL:GRB2 binds p-FRS2:activated FGFR2
findings: []
- id: Reactome:R-HSA-5654748
title: p-4Y-PLCG1 dissociates from activated FGFR2 mutants
findings: []
- id: Reactome:R-HSA-5655233
title: Activated FGFR2 mutants:p-FRS2 binds GRB2-SOS1
findings: []
- id: Reactome:R-HSA-5655241
title: Activated FGFR2 mutants:p-FRS2:GRB2:SOS1 activates RAS nucleotide
exchange
findings: []
- id: Reactome:R-HSA-5655245
title: Activated FGFR2 mutants:p-FRS2:GRB2:GAB1:PIK3R1 binds PIK3CA
findings: []
- id: Reactome:R-HSA-5655268
title: Activated FGFR2 mutants phosphorylate FRS2
findings: []
- id: Reactome:R-HSA-5655301
title: Activated FGFR2 mutants phosphorylate PLCG1
findings: []
- id: Reactome:R-HSA-5655320
title: Activated FGFR2 mutants:p-FRS2 binds GRB2:GAB1:PIK3R1
findings: []
- id: Reactome:R-HSA-5655323
title: Activated FGFR2 mutant-associated PI3K phosphorylates PIP2 to PIP3
findings: []
- id: Reactome:R-HSA-5655339
title: Activated FGFR2 mutants bind FRS2
findings: []
- id: Reactome:R-HSA-5655343
title: Activated FGFR2 mutants bind PLCG1
findings: []
- id: Reactome:R-HSA-5672965
title: RAS GEFs promote RAS nucleotide exchange
findings: []
- id: Reactome:R-HSA-8853313
title: FGFR2 fusions autophosphorylate
findings: []
- id: Reactome:R-HSA-8853319
title: FGFR2 fusions dimerize
findings: []
- id: Reactome:R-NUL-8853328
title: Mouse FGFR2 IIIa TM binds FGF1,2 and full-length receptors
findings: []